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Antibodies can recognize a large number of molecular determinants (antigens) 
because of the diversity present in antibody combining sites. This diversity resides 
in regions of extensive amino acid variability termed variable (V) regions. Variable 
region diversity is encoded in multiple germline variable region genes and can also 
arise from somatic modification of these genes. An important class of somatic 
modifications is the rearrangement of gene segments to form complete variable 
region genes. In this way complete V L genes arise from the joining of V L and J L gene 
segments while V H genes arise from V H' D, and J H gene segment joining. 
Studies of the V region protein sequences of hybridoma and myeloma immuno-
globulins which bind phosphorylcholine show that IgM antibody V regions are con-
siderably less diverse than IgG and IgA V regions. A comparison of protein sequence 
data with experiments on germline DNA suggests that at least some V segment diversity 
in IgG and IgA antibodies is the result of somatic mutations. D segments from phos-
phorylcholine-binding IgM antibodies as well as from IgG and IgA antibodies show 
extensive amino acid interchanges and size differences. In addition, diversity in 
the antibody response to phosphorylcholine is generated by associating a single V H 
region with at least two different V L regions. 
The complete sequences of the V L and V H regions from two antibodies binding 
8 (2+ 1) levan have also been determined. A comparison of these sequences to protein 
sequence data from other 8 (2 + 1) levan-binding proteins and to a germline DNA 
sequence suggests that the levan-binding proteins may arise from multiple germline genes 
differing at the protein level by only a few amino acids. Unlike the D segments of the 
phosphorylcholine binding proteins, the levan-binding immunoglobulin D segments show 
very little diversity. In addition, the protein sequences of levan-binding immunoglobulins 
can be compared to published V region idiotype and antigen binding studies. These 
v 
comparisons show that idiotypes may focus on certain sections of antibody V regions, 
and hence be of limited value as a probe of antibody V region fine structure. 
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Short-lived organisms can avoid many pathogens by virtue of their abbreviated 
life spans (1). This is possible whenever the time required for pathogenic discovery 
and invasion is of the same order as or longer than a complete life cycle of the 
invaded organism. Long-lived organisms, on the other hand, are far more apparent 
to potential pathogenic invaders. A highly developed immune system is required 
to preserve the integrity of these organisms in the face of repeated invasion by 
a wide variety of disease-causing agents. 
The vertebrate immune system has several features which are appropriate 
for long-lived organisms. It can learn to recognize common environmental pathogens 
and to respond to them in an enhanced, or secondary, fashion (2). This ability to 
launch a secondary immune response would be important only to an organism likely 
to live long enough to encounter a pathogen more than once in its lifetime. In 
addition, the vertebrate immune system has the ability to recognize a virtually 
unlimited array of molecular determinants (2). An organism which relies on a long 
life span for reproductive success must be prepared for encounters with pathogens 
which can rapidly change their physical appearance. It is this· property of the 
vertebrate immune system, the ability to recognize a tremendous array of molecular 
determinants, which is the primary focus of this diss.ertation. 
Vertebrate immune systems seem to have evolved a set of effector mechanisms 
based on fundamental properties of invading pathogens. These effector mechanisms 
include complement fixation, phagocytosis, and various lymphocyte and leukocyte 
cytotoxicities (2). Because of the fundamental nature of these effector mechanisms, 
it is apparently very difficult for pathogens to evolve ways to circumvent them. 
Thus the limited diversity of effector mechanisms is adequate to insure the destruc-
tion of most invading organisms. The ability to recognize and attack a large variety 
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of different molecular determinants, however, relies on a strategy directly contrasting 
with that used for immune effector functions. Rather than using a few receptors 
with broad specificity for invading pathogens, the immune recognition system has 
millions (or more) of recognition units capable of binding to multiple molecular 
structures (antigens) on virtually any pathogenic invader. 
The immune system of the laboratory mouse has been studied more extensively 
than that of any other animal. The following discussion, while generally true for 
most vertebrates, refers specifically to observations made on laboratory mice. 
Basic antibody structure (2) 
Antigen recognition structures are present on the products of both bone marrow-
derived (B) cells and thymus-derived (T) cells. The most abundant immune system 
antigen-recognition structure, the B-cell antibody, has several molecular forms 
based on a fundamental four-chain antibody unit. The antibody unit has two identical 
heavy (H) and two identical light (L) chains each containing variable (V) and constant 
( C) regions. There are two major classes of light chain C regions CX. and K) and five 
classes of heavy chain C regions ( µ, y, a., 0, ands). In the mouse, the y and A. classes 
each include several related C regions designated yl, y2a, y2b and y3, and A. 1 and 
A.2 (3). Immunoglobulin classes derive their names from their heavy chain C regions; 
i.e., IgM has a C region, IgG has a C region, etc. The IgG, IgD, IgE, and cell surface 
µ y 
IgM molecules are monomeric antibody units, the serum IgM molecule is constructed 
from five antibody units joined by a J polypeptide, and the IgA molecule can be 
monomeric or in oligomeric form with a J polypeptide and the polypeptide secretory 
piece. 
Immunoglobulin polypeptides are made up of repeating regions of homology 
of about 110 residues in length. Heavy chains have four (IgG, IgD, IgA) or five 
(IgM, IgE) such units and light chains have two. Antibody V regions are the N-terminal-
most heavy and light chain homology units and each V H region interacts with a single 
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V 1 region to form an antigen-binding site. Regions of exceptional variability, termed 
hypervariable regions, provide the residues which interact with antigen (4-7). Thus 
the position and amino acid sequence of the V 1 and V H hypervariable regions determine 
the antigen-binding specificities of antibodies. The ability of the vertebrate immune 
system to recognize a vast array of antigenic determinants is directly related to 
its ability to produce a large number of antibody variable regions and, especially, 
hypervariable regions. 
Basie antibody genetics 
Antibody heavy and light polypeptides are encoded by three unlinked families 
of genes: H, A, and K. The organization of genes within these families is shown 
in the figure. The light and heavy chain families each have V and J (joining) gene 
segments and C region genes. In addition, the heavy chain gene family contains 
gene segments termed D (diversity) segments. Though D segments are included 
in the figure, the essential facts of their organization are unknown. V and J gene 
segments (light chain) or V, D, and J gene segments (heavy chain) are joined together 
to form complete V genes before transcription occurs (8-10). The rearranged V 
genes are separated from the C genes by an intervening piece of DNA which is part 
of the transcription unit. The V and C coding regions are joined by RNA processing 
to give rise to a completed antibody mRNA (9, 11, 12). 
Heavy chain V regions can be expressed with any of the CH regions by the 
deletion of intervening DNA (13, 14). Thus in order to express a V H gene with the 
C yl gene, the stretch of DNA containing the C µ, C 0, and C y3 genes would have 
to be deleted (see figure). Each antibody CH region mediates different immune 
functions. Monomeric IgM and IgD molecules are cell surface receptors for early 
B-eells, IgA molecules are the primary antibodies in body secretions, IgG molecules 
cross the placenta, and IgE molecules cause histamine release from mast cells. 
In addition, IgG and pentamerie IgM are the major serum antibodies and can participate 
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Figure Legend 
The organization of antibody genes in BALB/c mice. H, A., and K gene families 
are each located on different chromosomes with linkage relationships as shown. 
Gene segments with unknown linkage relationships are separated by slash marks. 







































in the classic complement pathway. Thus the immune system can use CH switching 
as a way to associate several different effector functions with a single antigen 
recognition unit (2). 
The generation of antibody diversity 
The extensive sequence diversity seen in antibody V regions is, as noted above, 
directly responsible for the ability of the immune system to bind a large number 
of determinants. Investigations into the molecular aspects of this diversity have 
given rise to the following ideas about its generation. 
Germline diversity 
Many antibody gene segments are directly encoded in the germline. There 
appear to be approximately 200 to 500 light chain V gene segments (15) and possibly 
the same number of heavy chain V gene segments. There are four J1 (16, 17) and 
four JH gene segments (8, 10) and an unknown number of D segments (possibly five 
to ten) (18). 
Combinatorial joining 
Since the V H and V 1 gene segments end inside the third hypervariable region, 
third hypervariable region diversity can be created by combining V 1 gene segments 
with different J1 gene segments or V H gene segments with different D and JH 
gene segments (8, 10, 19, 20). Thus 200 V 1 gene segments and 4 J1 gene segments 
can produce 800 complete V 1 genes. In addition, gene segment joining gives rise 
to diversity at the V H-D, D-JH' and V 1 -J1 junctions (16, 17, 20-22). This diversity 
arises in part because gene segments can be joined at any of several nucleotides 
in their junction regions (21). For example, particular V 1 and J1 gene segments 
can give rise to multiple V 1 -J1 junction sequences by varying the V 1 -J1 junction 
point one to three nucleotides towards one or the other gene segment. Junctional 
diversity is seen as amino acid substitutions, deletions, and insertions (16, 17, 20-22). 
Because of D segment and D segment junctional diversity, the third hypervariable 
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region of the heavy chain is far more diverse than any other antibody hypervariable 
region. There may well be a greater number of third hypervariable region sequences 
than sequences in all other hypervariable regions combined. 
V H-V L combinatorial association 
This is possibly the most powerful step in antibody diversity amplificaton. 
If an animal produces 200 (V segment) x 10 (D segment) x 4 (J segment) V H regions 
and 200 (V segment) x 4 (J segment) V L regions, then combinatorial association of 
heavy and light chains increases the potential diversity to 8000 x 800 = 6.4 x 106 
antibodies. Probably no other step produces an amplification of this magnitude. 
If junctional diversity is taken into account in the above calculation (see Summary), 
the amplificaton due to combinatorial association is even larger. 
Somatic mutation 
Somatic mutation is, mechanistically, a difficult subject to discuss because 
it refers to a broad class of mechanisms of immunoglobulin gene alteration. Somatic 
mutation mechanisms include somatic recombination (23), hypermutation (24-26), 
and normal somatic mutation (27). In general, however, somatic mutation processes 
are pictured as changing germline sequences through the alteration, rather than 
rearrangement, of germline information. Thus processes which randomly introduce 
base changes, either as a result of normal DNA replication or through special mechanisms, 
comprise a broad class of postulated somatic mutational processes. Somatic mutation 
may provide the largest single incremental increase in V region sequences. If an 
organism makes 10 7 antibodies and each undergoes only one somatic mutation, then 
somatic mutations contribute an additional 10 7 antibodies to the immune system. 
An important question about somatic mutation is, how frequent and dependable 
is it? If an organism can rely on generating certain sequences or a certain number 
of sequences somatically, then there will be no selective advantage to the maintenance 
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of these sequences in the germline. Thus the reliability of somatic mutation will 
determine the extent to which it is important in the immune system. 
V region sequencing experiments 
Antibody V region amino acid sequences are relevant to a number of problems 
in immunology. V region sequencing studies have played important roles in the 
determination of the three dimensional structure of antibody V regions (7, 28), the 
molecular basis of antibody-antigen interactions (6, 29), the structure of V region 
genes (8-10), and the mechanisms of antibody diversity generation (30). Hence the 
antibodies selected for sequencing studies are determined by the problems being 
addressed. The following criteria were important in my selection of antibodies for 
the study of V region diversity. (i) It is most useful to study antibody V regions which 
are similar in sequence to one another. My study is primarily concerned with the 
diversity arising from somatic alterations and rearrangements of germline informa-
tion. Thus it is important to minimize the contribution of germline V segment vari-
ability. (ii) Patterns of antibody diversity only become apparent after the comparison 
of a number of closely related V region sequences. Determining V region sequences 
similar to sequences already available facilitates the accumulation of large numbers 
of closely related V region sequences. (iii) A detailed understanding of the origin 
and function of V region diversity requires an understanding of the function of individual 
amino acid residues. Studies of antibody three dimensional structure and antigen 
binding are necessary for such structure-function correlations. (iv) With the advent 
of recombinant DNA technology, V regions can be studied at the germline as well as 
at the somatic level. Germline DNA sequencing studies provide information vital 
to the study of antibody diversity. Thus it is important to select antibodies which 
are being studied at the DNA level as well as at the protein level. 
Using the above criteria, I selected the antibodies binding phosphorylcholine 
and 8 (2 ~ 1) levan for V region sequence analysis. Levan-binding and phosphorylcholine-
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binding V regions have been previously studied by protein sequence analysis (31-36). 
These V regions have been found to fall into closely related groups which differ 
from one another by less than six amino acids over their N-terminal 35 residues. 
Phosphorylcholine-binding and levan-binding antibodies have also been studied by 
three dimensional structure analysis (7, 37), antigen binding (29, 38), and recombinant 
DNA techniques (8; S. Crews, unpublished observations). The antibodies binding 
these two antigens provide an interesting comparison with one another in that the 
small phosphorylcholine seems to bind to a more heterogeneous collection of antibodies 
than does the larger levan determinant. 
My sequencing studies were done on homogeneous immunoglobulins derived 
by two procedures: myeloma induction (39) and the hybridoma technique (40). Each, 
as used in these studies, has its own advantages and faults. Myeloma tumors arise 
from antibody-secreting B cells in the peritoneal cavity of mice injected intra-
peritoneally with mineral oil (39). Myeloma sequence data must be examined with 
the following reservations: (i) Myeloma tumors have been passed through many 
generations of mice and may have accumulated mutations in their immunoglobulin 
genes unrelated to normal diversification mechanisms. (ii) Myeloma proteins may 
contain a different set of phosphorylcholine-specific immunoglobulins than does 
the normal serum. The C regions of myeloma proteins are predominantly a. (37), 
as compared to the y and µ found in normal serum. In addition, the set of variable 
regions expressed in the myeloma population is not identical to that expressed in 
the serum immunoglobulin population (41). On the other hand, hybridomas are recently 
derived from normal B cells, and, accordingly, there is less chance that variants 
arose during hybridoma passaging. Hybridoma immunoglobulins complement those 
from myeloma tumors in that hybridomas are splenic in origin and produce primarily 
IgG and IgM immunoglobulins. 
The hybridomas which we studied were raised in mice immunized with 
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phosphorylcholine, while the myelomas came from unimmunized mice. If V region 
diversity is influenced by the route of antigenic exposure, myeloma proteins may 
reflect natural V region diversity more accurately than hybridoma proteins. Except 
as noted above, the diversity in myeloma proteins is probably a result of normal 
routes of antigenic exposure. 
I chose phosphorylcholine-binding antibodies for my sequencing studies partly 
because of experiments on phosphorylcholine-binding myeloma proteins already 
under way. These experiments resulted in the six complete myeloma V H sequences 
described in chapter one (32). Chapters two and three discuss the data in chapter 
one in conjunction with sequence data from hybridoma proteins. 
The results of a preliminary screening study on the N-terminal 3'5 residues 
of 16 phosphorylcholine-binding hybridoma V Land V H regions are reported in 
chapter two (42). It is clear from these sequences that the IgG hybridoma antibodies 
have significantly more N-terminal diversity than the IgM hybridoma antibodies. 
The additional diversity seen in IgG antibodies probably results from the selective 
expansion of both germline and somatically-generated clones initially present at 
very low levels. This expansion of rare clones may be mediated by antigen and by 
V region sequence-specific regulation. Such sequence-specific regulation can occur 
through V region antigenic determinants called idiotypes (43). 
Chapter three describes the complete V H sequences of seven phosphorylcholine-
binding hybridoma proteins and the V H segment sequences of two additional proteins 
(44). These sequences, along with the sequences from chapter one, define more 
precisely the differences in diversity between IgM antibodies and IgG and IgA anti-
bodies. The V H segment diversity of µ chains is seen to be less than that in y and 
a chains. even though µ, y, and a chains have comparably diverse D segments. 
If these diversity differences between the V regions of different antibody classes 
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are the result of selection, then it should be possible to identify residues which are 
involved in such selection. The sequences reported in chapters one and three allow 
the identification of amino acid substitutions which may reflect this selection process. 
Phosphorylcholine-binding antibody D segments are relatively long and contain 
large numbers of amino acid substitutions, insertions, and deletions. Current studies 
in our lab of the DNA sequences of germline gene segments will allow an appraisal 
of the mechanisms necessary to generate this D segment diversity. In addition, 
a comparison of the sequences of germline phosphorylcholine-binding V H gene 
segments to protein V H sequences will hopefully provide a measure of the contribu-
tion of somatic mutation to V H region diversity. 
The second set of antigen-binding proteins, those binding B (2 -+ 1) levan, is 
discussed in chapter four (45). These proteins have V 
1 
and V H regions which differ 
by only four or less amino acids from prototype sequences, and which have only 
one amino acid interchange in their D segments. Despite this high degree of sequence 
homology, however, the V Hand V 
1 
segments may each be encoded by at least two 
germline genes. 
The complete characterization of these levan-binding V H and V 
1 
regions allows 
idiotype analysis and structure-function correlations to be carried out using well-
defined proteins. Such analyses are basic to an understanding of antibody diversity 
as they provide information on the roles of individual sequence differences. Knowledge 
of the function of individual residues is essential if the reasons underlying the selective 
expansion of germline and somatically generated genes are to be understood. In 
addition, antibody idiotypes have played a central role in many studies of antibody 
structure and genetics (se Ref. 46 for reviews). An understanding of the molecular 
basis of antibody idiotypes is central to the interpretation of such studies. 
The appendix contains a technical paper describing the high performance liquid 
chromatography of phenylthiohydantoin amino acids (47). Phenylthiohydantoin identi-
12 
fication by high performance liquid chromatography is one of the most significant 
improvements in protein sequence analysis of the past decade. It allows rapid identi-
fication and quantitation of all protein amino acids without additional time-consuming 
and error;..pran·e chemical modifications. 
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Chapter 1 
The complete amino acid sequences of six V H regions from 
myeloma proteins binding phosphorylcholine 
This manuscript will be submitted to Molecular Immunology 
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Introduction 
The enormous diversity available in the normal antibody repertoire remains 
one of immunology's most fascinating aspects. The search for the mechanisms responsible 
for this diversity has been pursued for well over a decade and many important features 
of antibody variability have been described. Antibody molecules are composed of 
heavy (H) and light (L) chains, each containing variable (V) and constant ( C) regions. 
V regions are constructed from several gene segments encoded separately in the 
germ line. Complete V L regions are created by the joining of V L and J L (joining) 
gene segments while V H' D (diversity) and JH segments are joined to form complete 
V H regions (1, 2). 
Antibody V segments are encoded by multiple germline genes (3) as are J segments 
(1, 4, 5) and, presumably, D segments (1). The V L -JLjunetion and the V H-D-JH 
junctions occur in the V L and V H third hypervariable regions. Thus, third hypervariable 
region diversity can be generated through the combinatorial joining of V Land JL 
gene segments (6, 7) and V H' D and JH gene segments (1, 8). Additional diversity 
may arise through somatic mutations in germline genes (9). 
In this paper we describe the complete sequences of six V H regions from phos-
phorylcholine-binding myeloma proteins. The diversity seen in these sequences, 
and in sequences from phosphorylcholine-binding V H regions reported elsewhere 
(10-13), provide an assessment of the V H phenotype of the antibody response to phos-
phorylcholine. Studies at the DNA level currently under way in our laboratory will 
determine the germline genotype of the phosphorylcholine-binding myeloma V H regions. 
A comparison of protein sequence phenotypic information to germline DNA sequences 
will provide a measure of the contribution of somatic mutation mechanisms to diversity. 
In addition, the D regions from phosphorylcholine-binding myeloma V H regions are 
quite variable and provide examples of the kinds of diversity which can arise from 
V H - D-J H joining. 
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Materials and Methods 
Myeloma heavy chain isolation 
Myeloma tumors were obtained from the Salk Institute and grown in ascites 
form in BALB/c and CDFl mice primed one month previously with 0.5 ml mineral 
oil. Ascites fluid was obtained from myeloma-bearing mice, filtered through Miracloth 
to remove macroscopic lipid complexes, and precipitated in 40% saturated (NH4)2so 4 
at 4°C. The precipitate was mildly reduced in 0.2 M Tris buffer, 2 mM EDTA, 10 mM 
dithiothreitol, pH 8.2, for 1 hr at room temperature and then alkylated for 1 hr at 
4°C by the addition of iodoacetamide to 25 mM. The reduced and alkylated protein 
was applied to a phosphorylcholine-sepharose 4B column (14), eluted with 10-3 M 
phosphorylcholine, desalted over G-25 in 0.2 M NH3 and lyophilized. These affinity 
column preparations contained purified myeloma proteins and were loaded on an 





heavy and light chain peaks were pooled separately and desalted on G-25, 0.2 M 
Cyanogen bromide digests 
Purified heavy chains were digested with 2.5% cyanogen bromide in 70% HCO 2H 
for 24 hr at 4°C. These digests were then diluted, lyophilized twice and applied to 




• Column peaks were 
desalted in 0.2 M NH20H or 5% HC02H. In some cases heavy chains were fully 
reduced and alkylated in the presence of 5 M guanidine before the CNBr digests. 






Automated sequence analysis 
Automatic sequence analysis was done using Beckman 890C and modified 890C 
sequenators (15), and a home-made solid phase sequenator. A Durrum D-500 Automatic 
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Amino Acid Analyzer, Hewlitt-Packard Gas Chromatograph, and Waters Associates 
High Performance Liquid Chromatograph (HPLC) were used to analyze sequencer 
samples (16, 17). Heavy chain variable regions are numbered as in Kabat et al. (18). 
Peptide map analyses 
Trypsin or chymotrypsin digests were performed at an enzyme:substrate ratio 
of 1:100 in 1 % NH
5
co3 for 1 hr at 37°C. Two-dimensional peptide paper maps at 
pH 3.5 were done using the procedure of Katz et al. (19). Analytical maps were 
dipped in 80:20:8 ethanol:acetic acid:collidine, 0.1 % ninhydrin and developed for 
12 min at 100°C. Prepatory maps were sprayed lightly with 0.1 % ninhydrin in ethanol, 
developed at 100°C, and the spots cut out and eluted immediately upon visualization. 
Acidic peptides were eluted in 0.5 M NH40H while basic peptides were eluted in 
10% HC02H. Electrophoresis at pH 6.5 was done in some cases to verify the assignment 
of amide residues on Eastman chromagram cellulose plates in 10:0.4:90 pyridine:acetic 
acid:water. After electrophoresis at 1000 volts for 30 min on a Desaga flat plate 
electrophoresis apparatus, spots were visualized with 0.1 % ninhydrin in acetone. 
Spots staying near the origin contain amide residues while those migrating towards 
the anode contain acids. Amino acid analysis was done on a Durrum D-500 amino 
acid analyzer after 18 hr hydrolysis of the peptides at 108°C in 6 N HCl. 
Cyanogen bromide fragment precipitation 
CN2 (see Results) cyanogen bromide fragments were desalted on P2 in 5% HC0
2
H, 
lyophilized, and redissolved in 10% acetic acid. Concentrated NH
4
0H was added 
until a white precipitate formed and the precipitate was spun out and lyophilized. 
This procedure is from Rudikoff and Potter (10). 
Results 
Isolation of cyanogen bromide fragments 
Figure la shows a typical G-100 profile of a mildly reduced and alkylated 
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Figure 1. Gel chromatography of CNBr fragments. 
(a) CNBr digest of a mildly reduced and alkylated heavy chain chromatographed 
on G-100 in 5 M guanidine, 0.2 M NH
5
Co3• 
(b) CNl peak from (a) fully reduced and alkylated and rechromatographed 
on G-100 in 5 M guanidine, 0.2 M NH
5 
C03• 
(c) CNBr digest of a fully reduced and alkylated heavy chain chromatographed 
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heavy chain CNBr digest. The first peak, CNl, contains a mixture of peptides including 
the peptide from 82a into the C region. This peak was desalted in 0.2 M NH4 OH, 
lyophilized, and reduced and aklylated in the presence of 5 M guanidine HCl. Figure lb 
shows a profile of CNl fully reduced and alkylated and rerun on G-100. The peak 
labeled CNlc contains only the peptide from 82a into the C region. 
The CN2 peak (Fig. la) was desalted in 5% HC02H due to its insolubility in 
dilute base and precipitated as in Materials and Methods. The precipitate contained 
only the fragment from 35 to 82 and will be referred to as CN2p. This CNBr fractionation 
procedure is the same as that in Rudikoff and Potter (10). 
In some cases the intact heavy chains were fully reduced and aklylated prior 
to CNBr digestion and run on an AcA54 column in 3 M guanidine, 0.2 M NH5co3• 
A column profile is shown in Fig. le. The V region fragment from 82a into the C 
region can be isolated cleanly as CNII while the fragment from 35 to 82 is contained 
as a mixture in CNill. 
Sequence determination 
The sequencing strategies discussed below are outlined in Fig. 2 for the S107 
VH region. 
Purified myeloma heavy chains were degraded 35 cycles by automatic sequenator 
to determine the N-terminal portion of the molecule. A plot of PTH-amino acid 
yield vs. cycle number is shown in Fig. 3 for the protein M511H. Ser' and Thr' refer 
to derivatives of serine and threonine resulting from secondary reactions during 
sequencing. While data condensed and presented as in Fig. 3 are more difficult to 
interpret than actual HPLC chromatograms, the M511H sequence is clearly visible. 
The average repetitive yield calculated using leucines at cycles 4, 11, and 20 is 93%. 
The CN2p fragments (positions 32 to 82) were usually sequenced for at least 
46 steps with the remainder of the fragment being determined from peptides. Compo-
sitions were obtained from CN2p tryptic or chymotryptic peptides and the ultimate 
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Figure 2. The sequencing strategy for the S107 V H region. All myeloma V H regions 
were sequenced in an identical fashion with the exception of certain regions depicted 
in Figure 4. 
Sequence determined by 890C automatic sequenator 
-----> Sequence determined by solid phase sequenator 
[ ] Tryptic peptide 





























































































































































































































































Figure 3. The N-terminal sequence of M511H. Ordinate values are proportional 
to the absorbance at 254 nanometers of the phenylthiohydantoin-amino acids at 
each sequenator cycle. Cycle number is plotted on the abscissa. Arrows indicate 
the M511H N-terminal amino acid sequence. SER' is a secondary reaction product 
of serine, and serine and threonine 254 A values are multiplied X3. The M511 heavy 
chain used in this sequenator run was mildly reduced and alklyated, and as a result 
no cystine was seen at position 22. Cystine is not plotted in this figure. 
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tryptic peptides were analyzed by automatic sequenator. In most cases the penultimate 
glutamine was verified by pH 6.5 electrophoresis. A summary of the CN2p sequencing 
strategies is shown in Fig. 4. 
CNlc fragments (residues 82a into the C region) were analyzed for 37 cycles 
by automatic sequenator. Figure 5 shows a plot of the HPLC data for HS CNlc. 
The alanines at residues 5, 14, and 29 give an average repetitive yield of 94%. 
Discussion* 
Figure 6 presents the complete V H sequence data from the phosphorylcholine-
binding myeloma proteins reported here and elsewhere (10, 11). These sequences 
have played an important role in the development of ideas about antibody diversity 
(20). These myeloma V H sequences exhibit two kinds of diversity: scattered amino 
acid substitutions in the V segment and extensive substitutions and size changes 
in the D segment. As germline T15 V H group gene sequences become available, 
it will be possible to determine the extent of somatic sequence variation within 
this set of proteins. In addition, the D segment changes provide important insight 
into the kinds of DNA rearrangements that must occur to generate D segment diversity. 
Together with other antiphosphorylcholine V H sequences (12, 13), the myeloma data 
presented in Figure 6 provide one of the primary models for the study of antibody 
diversity. 
Summary 
Closely related sets of proteins play a crucial role in the study of V region 
diversity. In this paper, we describe six complete V H region sequences from myeloma 
proteins with specificity for phosphorylcholine. 
* These data are discussed more completely in Chapters 2 and 3 in conjunction with 
sequences presented there. 
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Figure 4. The sequencing strategies for the myeloma CNB4 fragments from 35 to 
82 (CN2p fragments). 
* indicates amide verification by pH 6.5 electrophoresis (see Materials and 
Methods). 
( ) Chymotryptic peptide. 
Solid lines indicate identity to 863, and amino acid differences are designated 
by the one-letter code of Dayhoff (22). 

















































































































































































































































Figure 5. The sequence of the N-terminal 37 residues of the HS CNBr peptide 
beginning at residue 83. Ordinate, abscissa, and arrows are as in Figure 3. SER' 
and THR' are secondary reaction products of serine and threonine, and serine, threonine, 
SER', THR', and tryptophane are all multiplied by .the indicated scale factors. AMC 
stands for amidomethylcystine, the cystine derivative for med by complete reduction 
and alkylation of disulfide bonds. No methionine is present in this sequence and methionine 
































1 5 10 15 20 25 ae as 1 5 10 15 20 25 ae as 1 5 10 15 20 25 ae as 1 5 111 15 20 25 ae as 
CYa.E 
32 
Figure 6. A schematic representation of the complete V H sequence data from phos-
phorylcholine-binding myeloma proteins. Straight lines indicate identity to the Tl 5 
prototype sequence; a vertical bar indicates an insertion; ( ) indicates a deletion; 
and substitutions are designated by the one-letter code of Dayhoff (2 2). The position 
of each amino acid difference is shown at the bottom of the figure except in the 
third hypervariable region where every other position is numbered. Hypervariable 
regions are shown at the top of the figure (HV
1
, HV11, HV111> and V, D and J segment 
boundaries are shown at the bottom. M603 is from ref. 10 and T15 and M167 are 









































































































































































































































We thank Richard Douglas and Tim Hunkapiller for computer graphics. Note 
added in proof: Since the completion of this work, the V H region sequence of M511 
has been published in a separate study (21). This M511 V H sequence agrees with 
the sequence reported here. 
35 
References 
1. Early, P., Huang, H., Davis, M., Calame, K. and Hood, L. (1980) An immunoglobulin 
heavy chain variable region gene is generated from three segments of DNA: 
V H' D and JH. Cell 19: 981. 
2. Bernard, O., Hozumi, N. and Tonegawa, S. (1978) Sequences of mouse immuno-
globulin light chain genes before and after somatic changes. Cell 15: 1133. 
3. Seidman, J., Leder, A., Nau, M., Norman, B. and Leder, P. (1978) Antibody 
diversity. Science 202: 11. 
4. Max, E., Seidman, J. and Leder, P. (1979) Sequences of five potential recombi-
nation sites encoded close to an immunoglobulin K constant region gene. Proc. 
Nat. Acad. Sci. USA 76: 3450. 
5. Sakano, H., Maki, R., Kurosawa, Y., Roeder, W. and Tonegawa, S. (1980) 
Two types of somatic recombination are necessary for the generation of complete 
immunoglobulin heavy-chain genes. Nature 286: 676. 
6. Weigert, M., Gatmaitan, L., Loh, E., Schilling, J. and Hood, L. (1978) Rearrange-
ment of genetic information may produce immunoglobulin diversity. Nature 
276: 785. 
7. Weigert, M., Perry, R., Kelley, D., Hunkapiller, T., Schilling J. and Hood, L. 
(1980) The joining of V and J gene segments creates antibody diversity. Nature 
283: 497. 
8. Schilling, J., Clevinger, B., Davie, J. and Hood, L. (1980) Amino acid sequence 
of homogeneous antibodies to dextran and DNA rearrangements in heavy chain 
V-region gene segments. Nature 283: 35. 
9. Cohn, M., Blomberg, B., Geckler, W., Rashke, W., Riblet, R. and Weigert, M. 
(197 4) First order considerations in analyzing the generation of diversity. 
In The Immune System: Genes, Receptors, Signals. (Edited by E. Sarcarz, 
A. Williamson and C. Fox). Academic Press, New York. p. 89. 
36 
10. Rudikoff, S. and Potter, M. (1974) Variable region sequence of the heavy 
chain from a phosphocholine-binding myeloma protein. Biochemistry 13: 4033. 
11. Rudikoff, S. and Potter, M. (1976) Size differences among immunoglobulin 
heavy chains from phosphocholine-binding proteins. Proc. Nat. Acad. Sci. 
USA 73: 2109. 
12. Johnson, N., Gearhart, P., Douglas, R. and Hood, L. (1980) The amino acid 
sequences of nine V H regions from hybridomas binding phosphorylcholine. 
Manuscript in preparation. 
13. Gearhart, P., Johnson, N., Douglas, R. and Hood, L. (1980) IgG antibodies 
to phosphorylcholine exhibit more diversity than their IgM counterparts. 
Manuscript in preparation. 
14. Chesebro, B. and Metzger, H. (1972) Affinity labeling of a phosphorylcholine-
binding mouse myeloma protein. Biochemistry 11: 766. 
15. Hunkapiller, M. and Hood, L. (1978) Direct microsequence analysis of polypeptides 
using an improved sequenator, a nonprotein carrier, and high pressure liquid 
chromatography. Biochemistry 17: 2124. 
16. Johnson, N. D., Hunkapiller, M. and Hood, L. (1979) Analysis of phenylthiohydantoin 
amino acids by high performance liquid chromatography on DuPont Zorbax 
cyanopropylsilane columns. Anal. Biochem. 100: 335. 
17. Barstad, P., Farnsworth, V., Weigert, M., Cohn, M. and Hood, L. (1974) Mouse 
immunoglobulin heavy chains are coded by multiple germline variable region 
genes. Proc. Nat. Acad. Sci. USA 71: 4096. 
18. Kabat, E., Wu, T. T. and Bilofsky, H. (1979) Sequences of Immunoglobulin 
Chains. U.S. Department of Health, Education and Welfare. Public Health 
Service, National Institutes of Health. 
19. Katz, A., Dreyer, W. J. and Anfinson, C. B. (1959) Peptide separation by 
two-dimensional chromatography and electrophoresis. :!· Biol. Chem. 234: 2897. 
37 
20. Hood, L., Loh, E., Hubert, J., Barstad, P., Eaton, B., Early, P., Fuhrman, J., 
Johnson, N., Kronenberg, M. and Schilling, J. (1976) The structure and genetics 
of mouse immunoglobulins: an analysis of NZB myeloma proteins and sets 
of BALB/c myeloma proteins binding particular haptens. Cold Spring Harbor 
~· Quant. Biol. 41: 817. 
21. Robinson, E. and Apella, E. (1980) Complete amino acid sequence of a mouse 
immunoglobulin a chain (MOPC 511). Proc. Nat. Acad. Sci. USA 77: 4909. 
22. Dayhoff, M. (1976) Atlas of Protein Sequence and Structure. National Biomedical 
Research Foundation, Silver Spring, Maryland, 5: 189. 
38 
Chapter 2 
IgG antibodies to phosphorylcholine exhibit more diversity 
than their IgM counterparts 
This manuscript will be submitted to the Journal of Experimental Medicine 
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Introduction 
One goal in molecular immunology is to understand the mechanisms responsible 
for antibody gene diversification. The antibody molecule is composed of two light 
(L)1 and two heavy (H) polypeptides, both of which have a variable (V) and a constant 
( C) region. Antibodies binding to the simple hapten phosphorylcholine have served 
as a model for the cellular and molecular analyses of the immune response for several 
reasons. First, a closely related set of eleven myeloma proteins that bind phosphoryl-
choline have been isolated from BALB/c mice (1). Complete amino acid sequence 
analyses of the V H regions from nine of the proteins reveal that four V H regions 
are identical, and the remainder differ from these by one to 13 amino acid substitutions 
and occasional sequence insertions or deletions (2, 3). Approximately two-thirds 
of the substitutions fall within the third hypervariable region. The phosphorylcholine 
V H regions and other sets of closely related variable regions have permitted us to 
place important constraints on mechanisms of antibody diversification (4-7). Second, 
anti-idiotypic sera have been raised against several of the myeloma proteins binding 
phosphorylcholine. These antisera have revealed that the majority of anti-phosphorylcholir 
antibodies from BALB/c mice have the idiotype of the myeloma protein T15 (8-11). 
A variety of interesting analyses have subsequently been carried out on the developmental 
expression (12), genetic mapping (13, 14), and regulation (15-18) of this predominant 
idiotype. 
Because the initial amino acid sequence analyses were carried out on myeloma 
V regions, several concerns arise about the generality of the observed diversity patterns. 
1) Myeloma tumors have been passed through many generations of mice and may 
have accumulated somatic mutations in their antibody genes unrelated to normal 
diversification mechanisms. 2) Myeloma proteins contain a different subset' of 
phosphorylcholine-specific immunoglobulins than does the normal serum. The constant 
42 
regions of myeloma proteins are predominantly a (1), as compared to the y and µ 
found in normal serum. In addition, the set of variable regions expressed in the 
myeloma population is not identical to that expressed in the normal serum immuno-
globulin population (19). In order to circumvent these limitations of the myeloma 
system, we have employed the hybridoma technique of Kohler and Milstein (20) to 
obtain homogeneous antibodies from normal spleen cells in BALB/c mice immunized 
against phosphorylcholine. We reasoned that hybridoma cells are recently derived 
from normal B cells, and, accordingly, there would be less chance for somatic variants 
to arise during the more limited number of passages of the hybridoma cell lines. 
In addition, the hybridoma technique appears to accurately reflect the class distribution 
of splenic B cells. We report here the N-terminal amino acid sequences for the 
V H and V L regions of 16 hybridoma antibodies which bind phosphorylcholine. The 
most striking observation is that the IgG antibodies exhibit far more diversity than 
their IgM counterparts. The data also suggest that somatic variation may play a 
role in V region diversification. 
Materials and Methods 
Mice and immunizations 
BALB/cJ mice were purchased from the Jackson Laboratory, Bar Harbor, Maine. 
Mice at eight weeks of age were immunized intraperitoneally with 0.1 mg of phosphoryl-
choline-hemocyanin (11) in complete Freund's adjuvant. One to two months later 
(four days prior to cell fusion), they were injected intraperitoneally with 0.1 mg 
of phosphorylcholine-hemocyanin in complete Freund's adjuvant. 
Cell fusion 
The cells from individual spleens were added to 10-20 x 106 SP2/0-Ag14 cells, 
which do not secrete immunoglobulin (21), and then were fused according to Kennett 
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et al. (22). Hybrid cells were cloned in agar. Hybrid cell lines producing antibody 
to phosphorylcholine were produced by the same procedure in two other laboratories. 
The M8(1F8), G5(1B6), G6(2F5), G8(2B4), G9(1G9), G10(2C5), G14(1Bl0), Gl5(24B5), 
and G16(1D8) hybridomas were obtained from J. Hurwitz (23). The M3(63b4) and 
M4(64a5) hybridomas were obtained from B. Clevinger and J. Davie, Washington 
University, St. Louis, Missouri, and were generated from adult mice which were 
suppressed for expression of the T15 idiotype by treatment with anti-T15 serum 
at birth. The numbers in parentheses refer to the nomenclature of the donor laboratory. 
Radioimmunoassays for CH region and idiotype 
Antibodies against phosphorylcholine from hybridoma culture fluids were bound 
to phosphorylcholine-bovine serum albumin-coated plastic microtiter plates. The 
microtiter plates were then rinsed and 1251 rabbit anti-murine Fab, anti-µ, anti-yl, 
or anti-y3 antibody was added to determine the class of the phosphorylcholine-specific 
hybridoma immunoglobulins (24). Antibody with the T15 idiotype was detected by 
the inhibition of the binding of 125I-T15 to plastic tubes coated with A/He anti-
Tl 5 serum (11). 
Antibody purification 
Hybridoma cells were grown as ascites in BALB/c mice, and the ascites fluids 
were precipitated at 50% saturation with ammonium sulfate and resuspended in 
0.017 M boric acid, 0.03 M sodium borate, 0.15 M sodium chloride, pH 8.0. The 
antibody was then absorbed to a phosphorylcholine-glycyltyrosine-Sepharose column 
(25), and eluted with 10-2 M phosphorylcholine. 
Equilibrium dialysis 
Phosphoryl(methyl-14c)choline was purchased from New England Nuclear, 
Boston, Massachusetts. Antibodies were exhaustively dialyzed against 0.17 M boric 
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acid, 0.03 M sodium borate, 0.15 M sodium chloride, pH 8.0 with 2% sodium azide 
to remove photphorylcholine bound during affinity chromatography. Equilibrium 
dialysis was performed at 25°C in 0.1 ml compartments at an antibody concentration 
of 1.5-3.5 mg/ml. Protein molarity was determined by absorbance at 280 nm using 
E01•
1% = 1.37, and a molecular weight of 150,000 for IgG and IgA, and 170,000 for cm 
IgM. The data were plotted by the method of Scatchard (26) to calculate number 
of sites and by the Sips distribution function (27) to calculate Ka. A least squares 
fit was used to obtain the best line. 
Protein sequence determination 
The N-terminal amino acid sequences of light and heavy chains were determined 
by two different procedures. 1) Individual antibodies were dialyzed against 0.1 M 
ammonium chloride and the light and heavy chains were sequenced simultaneously. 
The residue assignments to light and heavy chains were made based on homology 
considerations. Because of the high degree of sequence conservation among these 
immunoglobulins, and because of our ability to quantify precisely the phenylthiohydantoin 
derivatives (28), we are cpnf ident of the data obtained using this rapid approach 
to N-terminal sequence analysis. Immunoglobulins GS and G15 were analyzed in 
this manner. 2) Antibodies were reduced in 8 M guanidine, 50 mM dithiothreitol, 
and 0.5 M Tris at pH 8.2 at 37°C for 1 h, and alkylated for 1 hat 4°C by the 
addition of 110 mM recrystallized iodoacetamide. The heavy and light chains 
were then separated on Ultrogel AcA34 (LKB Instruments, Inc., Rockville, Mary-
land) in 3M guanidine-0.2 M ammonium bicarbonate, and the protein fractions 
were desalted on Sephadex G-25 in 0.2 M ammonium hydroxide. The desalted heavy 
and light chain pools were lyophilized and individually subjected to automatic amino 
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acid sequence analysis on a modified 890B Beckman sequencer (29) or, in some cases, 
only the heavy chain was sequenced. If the heavy chain alone was sequenced, the 
light chain sequence was obtained by subtraction from the alternatives determined 
as described in procedure 1). The Ml, M2, M3, M4, M5, M6, MS, G3, G6, G9, GlO, 
G14 and G16 immunoglobulins were analyzed in this fashion. 
Results 
The V H regions from phosphorylcholine-binding immunoglobulins fall into 
one VH group 
The N-terminal amino acid sequences of the V H regions from eleven IgM 
hybridomas, nine IgG hybridomas and nine IgA myeloma proteins that bind phosphoryl-
choline are shown in Figure 1. Immunoglobulin V H regions which differ by two or 
less amino acids over their N-terminal 27 residues are classified as members of 
a single~ (1). As seen in Figure 1, all 29 V H regions fall within a single V H 
group. Twenty-two of the V H sequences are identical, and six of the remaining 
seven V H regions differ by a single residue from the prototype T15 sequence. The 
remaining V H region G14, differs by six residues. The 12 differences from T15 in 
these V H regions occur at 10 different positions with two identical substitutions 
seen at position 28 and two nonidentical substitutions at position 29. Eleven of 12 
substitutions can be explained by single nucleotide substitutions, and eight of 12 
substitutions lie outside the first hypervariable region as defined by Kabat et al. (30). 
The V L regions from phosphorylcholine-binding immunoglobulins fall into 
three V L groups 
The N-terminal amino acid sequences of 30 V L regions from immunoglobulins 
binding phosphorylcholine are given in Figure 2. The data indicate that the 30 V L 
regions fall into three groups. These three groups are the same as those initially 
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Figure 1. V H regions of phosphorylcholine-binding antibodies. Amino acids are noted 
by the one-letter code of Dayhoff ( 46). HVl designates the first hypervariable region. 
All * proteins come from one mouse, while the t proteins come from a second mouse. 
Other proteins each come from a different individual. The. sequences of HPC16, 
HPC35, HPC42, and HPC26 are from ref. 18, M603 is from ref. 45, M167 and W3207 



















































































































































































































































































































































































































































Figure 2. V 
1 
regions of phosphorylcholine-binding antibodies. V 
1 
sequences are 
categorized according to T15, M603 and M167 V 
1 
groups with the most typical protein 
of each group used as the prototype. The sequence of HPC16 is written assuming 
Asx residues are identical to prototype asparagine or aspartic acid residues. Parentheses 
( ) indicate probable assignments. HVl, *, t, as in Figure 1. The sequences of HPC19, 
HPC104, HPC52, HPC126, and HPC16 are from ref. 18, M167, 863, W3207, and M511 


































































































































































































































































































































































delineated by analysis of light chains from myeloma proteins binding phosphorylcholine, 
and are known as the T15, M603, and M167 groups (31). Light chains derived from 
antibodies to phosphorylcholine generated in mouse strains other than BALB/c also 
fall into these same three V L groups (32). Fourteen of 15 V L regions in the T15 
group are identical, and the 15th differs by a single residue substitution which can 
be explained by a single nucleotide change. Three of six V L regions in the M603 
group are identical and the other three differ by two, two and five residues. All 
of these substitutions can be accounted for by single nucleotide changes. Four of 
nine V L regions in the M167 group are identical and the others differ by a single 
residue. Three of these substitutions require two nucleotide changes (G5, GS and 
HPC16). Seven of the 15 substitutions noted in these groups fall outside the first 
hypervariable region as defined by Kabat et al. (30). There appe&rs to be more diversity 
in the M603 and M167 V L groups than in the T15 group. 
The T15 idiotype is present on immunoglobulins with sequence heterogeneity 
in V 11 and V L regions 
Antisera recognizing the T15 idiotype have been used as a probe to identify 
a restricted group of antibodies that bind to phosphorylcholine. The immunoglobulin 
class and idiotype classification of antibodies are given in Figures 1 and 2 and Table I, 
and show that antibodies with the T15 idiotype are found among proteins of the 
IgM, IgG3, and IgA classes. The data in Figures 1 and 2 also show that antibodies 
with the T15 idiotype can have different amino acid sequences in their V regions. 
Four hybridoma antibodies (Ml, M2, M5, and HPC52) and five myeloma proteins 
(S63, Y5236, HS, S107 and T15) exhibit the T15 idiotype and have identical N-terminal 
V Hand V L sequences. However, hybridomas G3, G9, and G16 express the T15 idiotype 
but differ from the proteins described above by one residue either in the V H (G9 
and G16) or the V L (G3) region. These data clearly indicate that antibodies with 
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TABLE I 
Affinity of Antibodies for Phosphorylcholine 
Antibodies 

















































*Equilibrium dialysis experiments were performed at 25°C. Binding constants 
were accurate to +10%. 
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The T15 idiotype comprise a family of closely related but distinct V regions, and, 
in this regard, are similar to immunoglobulins which bind dextran (33). 
Affinity for phosphorylcholine does not correlate with heavy chain class 
The affinity constants for various phosphorylcholine-binding immunoglobulins 
are given in Table 1. The Scatchard plots were linear, and the number of binding 
sites ranged from 1. 7 to 2.0 for monomeric forms. Values of a., the heterogeneity 
index, were calculated by the Sips distribution function and ranged from 0.9 to 1.06, 
indicating homogeneity of binding sites. The association constants cover a 30-fold 
range from 0.13 to 4.4 x 105 M-1. There is no significant difference in the average 
affinity of IgM versus IgG antibodies. 
Disc~ion 
The hybridoma technigue permits an examination of the normal antibody 
repertoire in the spleen 
The myeloma and hybridoma immunoglobulins binding phosphorylcholine differ 
in one striking feature - their class distribution. Hybridoma antibodies are of the 
IgM and IgG heavy chain classes, whereas the myeloma proteins are of the IgA class 
(Fig. 1). This nonoverlapping distribution of classes is probably due to the different 
origins of hybridoma and myeloma cells. The hybridoma antibodies were obtained 
from immunized spleen cells, whereas the myeloma proteins were synthesized by 
B cells in the peritoneal cavity. It has been previously shown that B cells specific 
for phosphorylcholine from gut-associated lymphoid tissues primarily give rise to 
IgA-producing clones, whereas clones derived from splenic B cells produce mainly 
IgM, IgG, and lg A (34). The fact that the gut-associated lymphoid tissues receive 
different antigenic exposures than the spleen suggests that different repertoires 
of V regions will be selectively expressed in the corresponding populations of B cells. 
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Thus the hybridoma process may transform a different population of B cells than 
the myeloma process~ 
The hybridoma technique also allows one to analyze many B cells from an 
individual mouse, whereas each myeloma tumor comes from a different mouse. 
For example, four of the seven nonprototype V H sequences and three of the nine 
nonprototype V L regions come from hybridomas generated in a single mouse (Figures 1 
and 2). This observation underscores the fact that extensive antibody heterogeneity 
is a property of individual mice and not just of the population of BALB/c mice. 
Another important advantage of the hybridoma technique is the possibility 
for experimental manipulation of the animal's immune response prior to cell fusion. 
For example, the idiotypic characterization and N-terminal sequence analysis of 
five hybridoma IgM antibodies to phosphorylcholine from mice suppressed for the 
T15 idiotype have recently been examined (HPC104, HPC126, HPC19, HPC16, HPC35) 
(17, 18) in addition to the two reported here (M3, M4). Five V H regions fall into 
the T15 group and the remaining two are derived from a new V H group (HPC19 and 
HPC104, not shown). Three V L regions are of the M167 group, three are of the M603 
group, and one is derived from a different V L group (HPC35, not shown). No light 
chains of the T15 V L group were noted. The suppression of the T15 idiotY.pe clearly 
selects against B cells expressing the Tl 5 V L group. 
Does somatic variation occur in the V H segments derived from immunoglobulins 
binding phosphorylcholine? 
The V H region is encoded by three distinct gene segments-V (variable), D (diversity), 
and J (joining) (33, 35 ). The V H gene segment encodes approximately residues 1-99. 
The question arises as to whether V segment (that portion of the V region encoded 
by the V gene segment) diversity arises entirely from multiple germline genes, or 
whether some of the diversity must occur by somatic variation. A cloned V H probe 
derived from a full length cDNA copy of the heavy chain mRNA derived from the 
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8107 myeloma tumor (36) has been used to analyze undifferentiated (embryo) DNA 
by Southern blot analysis (37). [The 8107 and T15 V H regions are identical in sequence 
(3).] Approximately eight to nine restriction fragments hybridize with this probe. 
Experiments have demonstrated that the 8107 V H probe cross-reacts with mRNAs 
from M167 and M603 (36). Because these are among the most different V H regions 
from phosphorylcholine-binding immunoglobulins (3), the 8107 cDNA probe should 
detect most, if not all, of the V H genes in the T15 group. If each fragment hybridizing 
with the 8107 cDN A probe contains one V H gene segment belonging to the T15 V H 
group, then there appear to be eight or nine V H germline genes of the T15 V H group. 
One can next ask, how many different V H gene segments are present among the 
phosphorylcholine-specific myeloma and hybridoma proteins sequenced to date? 
Among the nine myeloma V H regions that are completely sequenced, four differ 
in their V segments from the Tl5 V H region by one to seven residues (3). Among 
the 20 hybridoma V H regions that have been examined over their N-terminus, five 
differ from the T15 V H region and from the myeloma V H variants. Additional sequence 
data on the V H region of G3 also demonstrate that it differs from the T15 V H sequences 
(38). Thus, in the 29 V H regions derived from immunoglobulins binding phosphorylcholine, 
11 different V H segments are present. This is more than the expected number of 
phosphorylcholine-specific V H gene segments. Additional sequence analysis of the 
hybridomas now available, as well as the analysis of new examples, will almost certainly 
increase the number of V H segment variants well beyond the number of germline V H 
gene segments encoding the T15 V H group. Accordingly, even if nine somewhat under-
estimates the number of Tl5 V H-like gene segments, the observed phenotypic variation 
suggests that a portion of the V segment diversity arises by somatic variation. It is 
interesting to note, as judged by the data in Figure 1, that variation occurs as frequently 
outside as within the hypervariable region (8 or 12 V H substitutions are outside the first 
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hypervariable region). Accordingly, either the framework variants arise from distinct 
germline V H gene segments or the presumptive mechanism for somatic variation 
is not confined to the hypervariable segments. 
An alternative explanation for the V region diversity that we have noted above 
is the possibility of genetic polymorphism in V gene segments among mice of the 
BALB/c strain. Although we cannot rule this possibility out, we feel it is unlikely 
for several reasons. First, BALB/c mice have been inbred for hundreds of generations 
and mice obtained from a single source should be greater than 99% homozygous 
(39). Second, restriction digests of the DNAs from individuals and pools of mice 
have never shown any polymorphisms in C genes from BALB/c mice. Finally, the 
polymorphism would presumably have to be far more extensive than that known 
for other well-studied systems (e.g., globins and haptoglobins) in order to explain 
the extensive V region diversity that we have noted here. Admittedly, comparisons 
between multigene families such as the immunoglobulin V genes and the genes coding 
for C regions, glob ins, and hap tog lob ins are not entirely valid. Nonetheless, we feel 
that the above observations are relevant. Therefore it appears likely that the V region 
variation arises from multiple germline V gene segments and possibly some mechanism 
for somatic variation. 
IgG antibodies binding phosphorylcholine exhibit more diversity than their IgM counterparts 
The V H regions from 11 IgM hybridomas do not show any diversity in their 
N-terminal 37 residues (Fig. 1). In contrast, the corresponding portions of the V H 
regions from IgG hybridomas vary in six of the nine examples studied. The same 
pattern is seen in the corresponding V L regions (Fig. 2). Eleven of 12 IgM light chains 
are identical in sequence to the prototype sequence of their respective groups while 
five of nine IgG V L regions vary. Thus eight out of nine of the IgG antibodies vary 
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from the V group prototype sequences in either their V H or V L regions, whereas 
only one of the 10 IgM antibodies varies. Only 10 IgM antibodies are used in this comparison 
because the heavy chains of HPC19 and HPC104 do not belong to the T15 V H group, 
and the light chain of HPC35 does not belong to the Tl5, M603, or M167 V L group 
(18). 
One possible explanation for these differences between IgG and IgM proteins 
is that both arise from the same population and the differences are due to sampling 
errors. We used Fisher's exact method to demonstrate that it is very unlikely that 
these differences arise by sampling error. The probablility that V L regions of the 
IgM molecules and the V L regions of the IgG molecules were selected from the same 
population is less than 0.05; likewise, the probability that the V H regions from the 
IgM and IgG molecules were drawn from the same pool is 0.01; finally, the probability 
that both the V L and V H regions of these molecules were drawn from common populations 
is less than 0.005. Thus the IgG polypeptides are significantly more diverse than 
their IgM counterparts. 
Recombinant DNA studies have suggested that IgG- and IgA-producing cells 
are generally derived from B cells initially producing IgM (40-43). Thus the greater 
diversity of the IgG hybridomas must arise from infrequent variants, either in IgM-
or IgG-producing B cells, which are selectively expanded and expressed in IgG-producing 
cells. (In this discussion the word variant refers to a nonprototype sequence of either 
somatic or germline origin.) Two important questions arise. First, how and when 
are the infrequent variants generated? Second, what selective pressures give rise 
to the differences between IgM and IgG diversity? 
The infrequent variant clones which undergo expansion to create IgG diversity 
may arise either by somatic variation or may be encoded by germline V gene segments. 
Our data suggest that both of these sources may contribute such variant clones. 
For example, the M167 V L group, while encoded in the germline separately from 
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M603 V L and T15 V L groups, is not seen in the six IgM light chain sequences from 
unsuppressed mice. In mice suppressed with anti-T15 sera, however, three out of 
seven IgM antibodies express the Ml67 V L group (only one IgM expresses both the 
T15 V H and the M167 V L). Four out of nine IgG antibodies from unsuppressed mice 
also express the M167 V L group. Thus it appears that the T15 V L group is dominant 
in the IgM pool in normal mice but that suppression allows infrequent IgM M167 
V L group clones to be observed. These IgM M167 V L group clones increase in frequency 
in the IgG pool. As discussed earlier, somatic diversification also may account 
for some of the observed sequence differences in the IgG pool. 
The time at which variants are first expressed cannot be determined from 
these data. Some variants are probably encoded in the germline and arise early 
in differentiation. Somatic variants may be created as a result of normal somatic 
mutation or by special mutational mechanisms. Such somatic mutation processes 
could operate in IgM- or IgG-producing cells, in cells switching from IgM to IgG, 
or in cells triggered by antigen. 
One may envision two types of selection operating on germline or somatic variants 
which could result in the observed lgM-lgG diversity difference. i) Antigen-driven selectior 
Variant B-cell clones may be expanded as the result of increased affinity for antigen. 
As IgG-producing cell populations have undergone more antigen-driven selection 
than IgM populations, IgG antibodies should shown more variability than IgM antibodies 
(44 ). On the surface, the data present in Table I would appear to argue against this 
possibility. The range of affinity constants seen in the IgM and IgG antibodies are 
not signifi~antly different. However, these data do not exclude the possibility that 
the in vitro affinity of soluble antibody for free hapten could be significantly different 
than the affinity of cell surface antibodies for the hapten-carrier conjugate in vivo. 
Selection for variants in nonbinding site regions may occur whenever framework 
residues modify the positions of binding-site residues. ii) Idiotype selection. Selection 
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of infrequent variants may be accomplished by idiotype-specific regulation. For 
example, if idiotype-specific suppression helps control the level of predominant 
clones, then mutation away from such suppressed idiotypes would be a major selective 
advantage. As IgG-producing cells have undergone more soma tic generations than 
IgM-producing cells, selection will have had more opportunity to generate diversity 
in IgG molecules. Alternatively, IgM and IgG molecules may have unknown qualitative 
and quantitative differences in their idiotypic regulation. 
IgA antibodies, like IgG antibodies, are produced by secondary cells and have 
presumably undergone many rounds of antigen and idiotype-specific selection. This 
similarity would suggest that the diversity patterns of IgA antibodies should resemble 
those of IgG antibodies. However, only four out of nine IgA proteins differ from 
the prototype sequences shown in Figure 1, and there is only one amino acid difference 
in nine IgA V H N-termini. The IgA diversity appears intermediate between that 
of the IgG and IgM molecules. 
An analysis of the complete V H segments from five µ chains and four y chains 
from hybridomas binding phosphorylcholine has been carried out (38). A comparison 
of IgM V H segments with their nine IgA myeloma counterparts (2, 3, 45) suggests 
that the V H regions from a. chains are significantly more diverse than those from 
µ chains. Thus, the N-terminal 36 residues of the IgA V H regions give a misleading picture 
of the diversity in the remainder of the V H segment. The IgA as well as the IgG V H 
regions exhibit significantly more diversity than their IgM counterparts. 
Summary 
An amino acid sequence analysis of the N-terminal V H and V L regions from 
20 hybridoma and nine myeloma proteins directed against phosphorylcholine raises 
several interesting points. First, the V H segments of these immunoglobulins demonstrate 
sufficient variability to raise the possibility of somatic diversification. Second, 
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the IgG antibodies exhibit significantly more variability than their IgM counterparts. 
These data suggest that the selection of infrequent germline or somatically-generated 
clones gives rise to greater heterogeneity in the IgG pool than in the IgM pool. Lastly, 
the T15 idiotype represents a population of closely related but distinct V Hand V 
1 
regions. 
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An understanding of the mechanisms responsible for antibody diversity has 
been a goal that has intrigued biologists for the past 80 years. In the last few years, 
as a result of recombinant DNA techniques and protein sequence analyses, immunolo-
gists have been able to directly compare sequence information obtained from anti-
body genes and proteins and thereby have gained important insights into at least 
some of the mechanisms responsible for antibody diversity (1-4). 
Antibody molecules are composed of heavy (H) and light (L) chains which in 
turn are both divided into variable (V) and constant (C) regions. Comparative analyses 
of many variable regions demonstrate two important patterns. First, amino acid 
sequence variability is unevenly distributed throughout the V region. The antigen-
binding site is lined with extremely variable sections termed hypervariable regions, 
while nonbinding site, or framework, regions are more highly conserved (5-8). The 
existence of hypervariable regions has suggested that somatic mechanisms may 
play a role in diversity generation (9, 10). Second, V regions fall into sets or groups 
of closely related sequences (formerly termed subgroups) (11, 12). The minor variation 
within the V regions of a particular group has afforded special insights into mecha-
nisms of diversity (4, 12, 13). 
The antibody molecules are encoded by three unlinked families of genes--two 
light chain families, lambda (A.) and kappa (K), and a heavy chain family. The V L 
regions are encoded by two distinct gene segments, V L and J L (joining), whereas 
the V H regions appear to be encoded by three distinct gene segments, V 'H' D (diversity), 
and JH. The JL gene segments encode a small portion of the L chain third hyper-
variable region, whereas the D and JH gene segments encode most of the H chain 
third hypervariable region. The C regions for both light and heavy chains are encoded 
by C genes separate from the V genes (1, 14). 
Analyses at the protein and in certain cases the DNA level for several sets 
of closely related antibody V regions have provided important insights about mechanisms 
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for antibody diversity. i) There appear to be several hundred germline V K and V H 
gene segments. Thus germline diversity in these gene families is extensive (15). 
ii) There are four functional JH and J K gene segments (1, 16, 17). It appears that 
any JH gene segment may be joined with any V H gene segment and likewise any 
J~, gene segment with any VK gene segment. This co~binatorial joining is an im-
portant mechanism for amplifying diversity (18). iii) The site-specific recombination 




or V H' D, and JH gene segments may unite 
particular gene segments at different nucleotides and, accordingly, generate somatic 
variation at these junctions during the act of joining (16-18). iv) V regions appear 
to exhibit somatic variation beyond that which can be explained by the germline 
V gene repertoire and gene segment junctional diversity. In the V .A system this 
diversity appears exclusively in the hypervariable regions (10), but in several others 
it may be present in framework regions as well (19, 20). 
The first paper in this series described the N-terminal V Hand V 
1 
sequences 
for 16 hybridoma antibodies binding the simple hapten phosphorylcholine (21). Two 
interesting observations were made. First, somatic variation appears to be necessary 
to account for the diversity noted in the N-termini of the V H regions in these im muno-
globulins. Second, the V H regions from y chains are significantly more diverse than 
their µ counterparts. We report here the complete V H region sequences from seven 
hybridomas binding phosphorylcholine and the complete V H segment sequences of 
two additional hybridomas. These studies delineate in more detail the nature 
of diversity in the V H' D, and J H gene segments of phosphorylcholine antibodies 
and support the earlier observation that the V H regions from y chains are more 
diverse than their µ counterparts. 
Materials and Methods 
Isolation of Hybridoma Proteins. Hybridoma proteins were isolated as previously 
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described {21). 
Chain Separation. Hybridoma proteins were mildly reduced in 0.4 M 'T'ris, 
pH 8.2, 0.15 M NaCl, 2 mM EDTA, 30 mM DTT at room temperature for 1.5 hand 
alkylated at 4°C for 2 h in 65 mM recrystallized iodoacetamide. The reduced and 
alkylated proteins were precipitated by the dropwise addition of an equal volume 




at 4°C for at least 2 h and the precipitate collected by centrifu-
gation. The precipitate was then dissolved in 8 M guanidine HCl and diluted to either 
3 M or 5 M guanidine for chain separation. IgM and IgGl hybridomas were fractionated 
on LKB Ultrogel AcA34 in 3M guanidine HCl, 0.2 M NH5co3 while the IgG3 proteins, 
because of their tendency to aggregate, were fractionated on Pharmacia Sephacryl 
S-200 equilibrated in 5 M guanidine, 0.2 M NH5co3• Heavy chain peaks were desalted 
on Sephadex G-25 in 0.2 M NH3• 
Cyanogen Bromide Digests and Treatment of Cyanogen Bromide Fragments. 
Desalted and lyophilized heavy chains were digested with 2.5% cyanogen bromide 
in 70% HC02H for 24 h at 4°C. The digest was then diluted 12-fold, lyophilized 
twice, and applied to an LKB Ultrogel AcA54 column equilibrated in 3 M guanidine 
0.2 M NH4co3• After chromatography in guanidine, cyanogen bromide fragments 
were desalted on G-25 either in 0.2 M NH3 or 0.5 M NH3• All fragments from V 
region position 35 to 82 were desalted in 0.5 M NH3• 
Precipitation of the 35 to 82 fragment was adapted from Rudikoff and Potter 
{22). Briefly, the fragment was dissolved in 10% acetic acid and the pH was raised 
by the addition of concentrated NH40H until a precipitate formed. This precipitate 
was spun out in the cold and contained only the 35-82 fragment. 
Other Chemical Modifications. Complete reduction and alkylation was as 
above but performed in the presence of 8 M guanidine. 
Succinylation was performed in 0.2 M Tris, 8 M guanidine, pH 9.5 using a 20:1 
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weight ratio of succinic anhydride to protein. The pH was maintained with 2 N NaOH 
and an automatic titrator. Succinylated fragments were desalted on G-25 in 0.2 M 
NH
3
, lyophilized~ and cleaved at tryptophane residues in 35% cyanogen bromide, 
1:1 heptafluorobutyric acid:88% formic acid for 18 h at room temperature (23). 
This cleavage mixture was dried, redissolved in trifluoroacetic acid, and applied 
to the sequena tor. 
Amino Acid Sequence Determination. Automated sequence analysis was done 
on an extensively modified Beckman 890B protein sequenator (24) and the phenyl-
thiohydantoin amino acids determined using high performance liquid chromatography 
(25). 
Trypsin Digests and 2-Dimensional Paper Maps. Trypsin digests were done 
at a 1:100 w /w enzyme:substrate ratio. The digests were subjected to chromatography 
and electrophoresis on paper (26) and then lightly sprayed with 0.1 % ninhydrin in 
ethanol. Colors were developed for 6 min at 100°C and the spots cut out and extracted 
with 1 M NH
3 
(acidic peptides) or 5% HC0
2
H (basic peptides). 
Results 
Isolation of Cyanogen Bromide Fragments from the V H Region. Figs. 1 and 
2 show the cyanogen bromide gel filtration patterns of µ, yl, and y3 heavy chains. 
In each case the V region contains two methionines, Met 34 and Met 82. The cyanogen 
bromide fragment extending from positions 35 to Met 82 is labeled with the numeral 
I followed by the heavy chain class (Iµ, Iyl, Iy3), and the fragment from position 
83 into the C region is labeled with the numeral II followed by the heavy chain class 
(IIµ, II yl, II y3). 
The procedures for the isolation of the I peptides are shown in Fig. 1. The 
peptides Iy3 and Iµ can be isolated cleanly by a single dimension of gel filtration 
as shown in Figs. lA and lB. The I yl peptide can be· isolated either by precipitation 
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Figure 1. CNBr profiles of hybridoma heavy chains. Heavy chains were isolated, 











































Figure 2. Profiles of fully reduced and alkylated heavy chain CNBr fragments. 
Fragments were obtained as in Figure 1 and were fully reduced and alkyla ted and 
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away from contaminating peptides as described in Materials and Methods or by using 
only the low molecular weight component of the Iyl peak as shown in Fig. lC. 
The II peptides are contained as mixtures in CNl y3 (Fig. lA), CN4µ (Fig. lB), 
and CN4 yl (Fig. lC). Each of these peptide mixtures was fully reduced and alkylated 
and was refractionated on AcA54. In the case of the µ chains, the CNl peptide 
also was included to avoid losses due to disulfide interchange. The profiles of these 
chromatographic runs are shown in Fig. 2. The Ilyl and IIµ peptides can be isolated 
by pooling the designated peaks in Figs. 2A and 2B, while II y3 can be isolated cleanly 
by pooling only the first 40% of the appropriate peak in Fig. 2C. 
Heavy Chain Sequence Determination. A summary of the strategies for amino 
acid sequence analysis are shown schematically in Fig. 3. The N-terminal 38 residues 
of each heavy chain was determined by a single run on an intact chain. 
The I peptides were all sequenced for at least 36 cycles. In some cases the 
entire peptide was sequenced including the C-terminal homoserine, whereas in other 
cases residues 67 through 82 were determined by the complete sequence analysis 
of two smaller tryptic peptides isolated from paper (i.e., peptides including positions 
67 to 71 and 72 to 82). 
The II peptides were generally sequenced for 40 cycles to determine the re-
mainder of the V region sequence. However, in some cases the IIµ peptides washed 
out of the sequenator cup before the completion of the run. When this occurred, 
intact II peptides were succinylated, cleaved at the tryptophane residue, and sequenced. 
The tryptophane cleavage of succinylated IIµ peptides yields two peptides with un-
blocked N termini: one five residue peptide of known sequence (lOOC to 103) and 
one longer peptide of partially unknown sequence (104 to the C terminus of IIµ). 
A sequenator run on this mixture permitted the unambiguous determination of the 
remainder of the V region sequence. 
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Figure 3. V H region sequencing strategy. All of the hybridoma V H regions 
were sequenced in the same general way as outlined for the M3 protein in this figure. 
In some cases it was necessary to generate peptides from tryptic and tryptophane 
cleavages. These peptides are indicated in the figure. 
--> 
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amino acids determined by automatic sequenator 
tryptic peptide 
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tryptophane cleavage 

















































































The Hybridoma and Myeloma V H Regions Show Similar Patterns of Diversity. 
The V H regions from nine hybridoma antibodies to phosphorylcholine are compared 
to their nine myeloma counterparts in Fig. 4. M4 is sequenced to the end of the 
D segment and G9 is sequenced up to the end of the V segment. Three hybridoma 
and four myeloma V H regions are identical to the T15 prototype V H sequence. The 
variant hybridoma V H sequences differ by one to six residues from T15 and the variant 
myeloma V H sequences differ by one to 11 residues. In both the hybridoma and 
myeloma V H regions, insertions and deletions occur only in the third hypervariable 
region. In the hybridoma V H regions 16 of 21 (76%) variant residues are found in 
hypervariable regions, and similarly 22 of 29 (76%) variant residues in the myeloma 
V H regions are located in the hypervariable regions. Both hybridoma and myeloma 
V H regions are expressed with three V groups of light chains--the T15 V L group, 
the M603 V L group, and the M167 V L group. Since the basic patterns in the hybridoma 
and myeloma V H regions appear similar, we will consider both sets of data together 
in analyzing the diversity patterns in the V segments (residues 1-95), the D segments 
(residues 96-lOOa) and in the J segments (lOOb-113) which are encoded, respectively, 
by the V H' D, and JH gene segments. 
The V H Segments Demonstrate Diversity in the Framework as well as Hypervariable 
Regions. Nine V H segments are identical and 9 others differ by one to eight substi-
tutions. Generally the variant V segments di ff er by two or more widely scattered 
substitutions. Twenty-two variant residues are present at 15 different positions. 
Single base changes can account for 20 of 22 amino acid substitutions, and two substi-
tutions require two base changes. Four positions show variation in more than one 
V H region: position 53 has four amino acid substitutions, position 52c has two substi-
tutions, position 28 has an identical substitution in two V H regions, and two different 
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Figure 4. The V H regions from phosphorylcholine binding proteins. Hyper-
variable regions are shown at the top of the figure (HVl, HV2, and HV3) and V, D, 
and J segment boundaries are shown at the bottom. A solid line indicates identity 
to the T15 prototype, insertions and deletions are shown by residues above the solid 
line and by [ ] , and amino acid substitutions are labeled using the one-letter code 
by Dayhoff (31). Positions of amino acid substitutions are labeled at the bottom 
of the figure except in HV3 where every other residue is labeled. V 
1 
group, heavy 
chain class, and presence (+)or absence(-) of the Tl5 idiotype are shown for each 
sequence. The T15 and M167 sequences are from Ref. 3, the M603 sequence is 









































































































































































































































































































































































































































































































































































































































































































































amino acids occur in the three V H regions with variability at position 40. It is im-
portant to stress that no two of the variant V segments are identical. 
As was discussed in the preceding paper, the V H regions from immunoglobulins 
binding phosphorylcholine appear to be encoded by perhaps 8-9 V H gene segments. 
Accordingly, the V segment diversity noted in these heavy chains might arise from 
one of several sources: germline V H gene segments (15), ordinary somatic mutation 
(10), a special hypermutation mechanism (9), or by somatic recombination, presumably 
among related V H gene segments (15). 
D Segment Diversity is Extensive. If we count each insertion or deletion as 
well as amino acid substitutions, the D segment has 23 variant positions over 102 
residues analyzed. This D region variation tends to be clustered, since the ten 
variant proteins each average over two D segment substitutions. Fig. 4 demonstrates 
that the D segment diversity is of three types: i) isolated single base changes (e.g., 
position 99 in M167 and 100 in H8 and G3); ii) insertions or deletions at either end 
of the D segment (e.g., M4, G6, GlO, M603, M511, and M167); and iii) blocks of amino 
acid substitutions (e.g., W3207, M4, M6, and GlO). The single base substitutions 
could arise from the presence of multiple germline D gene segments or from somatic 
variatio11. The insertions or deletions of codons associated with either end of the 
D segment probably arise from the site-specific recombinational mechanism that 
joins the V Hand Dor the D and JH gene segments. This diversity arises because 
the actual DNA splice points may occur at different sites on each of these three 
gene segments, as has been well documented (16-19). The blocks of substitutions 
may arise from multiple germline D segments, from the splicing together of two 
germline D gene segments, or from a variety of other possibly somatic diversification 
mechanisms. 
D gene segments have not yet been isolated from germline DNA. Accordingly, 
we can only guess as to the number and diversity of germline D gene segments. 
83 
As a result of D segment variability, the heavy chain third hypervariable region 
is the most diverse V region segment. This can be clearly seen in the V H regions 
of immunoglobulins binding phosphorylcholine as well as those binding dextran (4). 
The JH Segments from Immunoglobulins Binding Phosphorylcholine are Encoded 
by One Germline JH Gene Segment. Mouse heavy chains are encoded by four dif-
ferent JH gene segments. In the 16 V H regions from hybridoma antibodies binding 
phosphorylcholine that can be compared, all appear to have J segments derived from 
the JHl gene segment. Five J segments have N-terminal substitutions and one JH 
segment has an additional single base substitution. The N-terminal residue from 
the JH segments of M6, GlO, M603, and W3207 is different than that of T15. The 
N-terminal two residues of the JH segment from M167 also differ from their T15 
counterpart. Three of these five JH segment changes are compatible with two base 
substitutions. Once, again, we feel this diversity can be explained by variability 
in the DNA splice point for joining the D and JH gene segments (16-18). The JH 
segment conservation seen in the phosphorylcholine-binding heavy chains provides 
a counterexample to the JH segment diversity seen in antibodies which bind dextran. 
In the 19 V H regions derived from hybridoma antibodies binding dextran, all four 
JH gene segments are expressed (4). 
The V H Segments from IgG Hybridoma and lg A Myeloma Immunoglobulins 
Binding Phosphorylcholine Show More Diversity than Their IgM Counterparts. An 
analysis of the N-terminal portions of ~hese V H regions discussed in the first paper 
in this series suggested that IgM V H regions were considerably less diverse than 
their IgG counterparts (21). For example, ten V H and V 
1 
N-termini from IgM hybridoma 
immunoglobulins showed only one one-base substitution when compared to prototype 
sequences of the corresponding V H groups. On the other hand, eight of nine IgG 
antibodies had from one to 11 differences. Using Fisher's exact method, the diversity 
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differences between IgM and IgG molecules are highly significant (p<.005). The 
extensive sequence data presented in this paper allow a more detailed comparison 
to be made between IgG, IgA, and IgM V H segments. Five of five V H segments from 
µ chains are identical to the Tl5 prototype sequences (Fig. 4). Four of four V H 
segments from y chains differ from the T15 prototype. Four of nine V H segments 
from a. chains differ from the T15 prototype. These data reinforce the early sup-
position that the y V H segments are more diverse than their µcounterparts. Moreover, 
the a. chains also appear to be significantly more diverse than their µcounterparts 
(p< 0.05), although they may be somewhat less diverse than their y counterparts. 
Possible explanations for these diversity differences have been discussed in the first 
paper of this series (21). 
Selection Imposes Several Constraints on the Immunoglobulins Binding Phos-
phorylcholine. The contact residues for phosphorylcholine binding are highly conserved. 
Padlan et al. have proposed that the heavy chain tyrosine 33 and arginine 52 are 
the principal hapten-contact residues for heavy chains. In addition, there are probably 
charge interactions with lysine 52b and glutamic acid 35 and van der Waals interactions 
with residues 98 and 99 (27). While residues 98 and 99 vary somewhat in the sample 
of proteins analyzed here, the V H regions in the T15 V H group from proteins which 
bind phosphorylcholine show considerable conservation of the other contact residues. 
In all of these V H regions sequenced to date, there are no substitutions at tyrosine 33, 
arginine 52, and lysine 52b and only one glutamic acid-serine interchange at position 
35. (The glutamic acid-serine interchange is from Ref. 21.) This conservation is 
consistent with the importance of these residues in the binding of phosphorylcholine. 
IgG and IgA antibodies show special diversity at residues 40 and 53. We have 
previously postulated that the diversity differences between IgM antibodies and 
IgG and IgA antibodies are the result of selection. Hence it is important to try 
to answer the question, is there any pattern to the amino acid variability in IgG 
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and IgM V H segments? We feel that Figure 4 includes at least two such patterns 
of sequence variability, even though the limited number of non-T15 sequences makes 
these patterns difficult to detect. D segment variability is excluded from this dis-
cussion because of its possible special diversification mechanisms. 
Ten out of 23 V H segment substitutions occur at five positions in the second 
hypervariable region. Four of these substitutions occur at residue 53. We feel 
that this increased sequence variability at and around residue 53 is significant. 
It may result from some form of selection or from an unknown site-specific hyper-
mutational mechanism. 
A second position with an unusual pattern of sequence variability is position 
40. M511, M167, and G6 have a hydroxyamino acid at position 40 while all other 
V H regions have proline. Position 40 is five residues outside of the first hypervariable 
region and is part of a loop that interacts strongly with the light chain (27). M511, 
M167, and G6 all have M167 L group light chains, while all but one of the other V H 
regions associate with T15 or M603 L group light chains. Thus the presence of a 
hydroxyamino acid at position 40 directly correlates with L chain group. The only 
exception to this is an IgM protein sequenced elsewhere which has a proline at residue 
40 and a M167 L group light chain. Thus the sequence· variation at residue 40 appe~rs 
to be present in IgG and IgA proteins though possibly absent or at low levels in IgM 
proteins. This difference in the variability of residue 40 between IgM antibodies 
and IgG and IgA antibodies is consistent with our previous observations about the 
lack of variability in IgM V segments (21). It suggests that some of the diversity 
present in IgG and IgA populations may result from selective pressures on amino acids 
involved in heavy-light chain interactions. 
Antibodies Binding Phosphorylcholine Demonstrate Combinatorial Association 
Between Light and Heavy Chains. Among the IgM immunoglobulins binding 
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phosphorylcholine, some employ the same heavy chain in conjunction with two very 
different light chains (e.g., M2 and M3 in Fig. 4). The Tl5- and M603-like V L regions 
differ by more than 50% of their amino acid sequence over their N-terminal 38 
residues (28). This is the first formal demonstration of the combinatorial association 
of light and heavy chains. The assumption has long been held that one heavy chain 
may pair with all the different light chains in a combinatorial manner (27). Indeed, 
if 1000 light and 1000 heavy chains can be associated combinatorially, 10
6 
different 
antibodies could be produced. Thus these data support the hypothesis that combinatorial 
association is a fundamental mechanism for information amplification in the immune 
system. It is interesting that this first example of combinatorial association generates 
antigen-binding sites which interact with the same hapten. 
The Tl5 Idiotype is Found on a Closely Related Set of Immunoglobulins. The 
Ml ( µ), M2 ( µ), G3 ( y3), and G6 ( y3) immunoglobulins express the Tl5 idiotype (21). 
Claflin and Cubberly have suggested, from idiotypic and isoelectric focusing data, that 
antibodies bearing the T15 idiotype on IgGl, IgG2 and IgG3 heavy chains in individual 
BALB/c mice are identical (29). While the V H regions of Ml and M2 are identical 
to the V H region of Tl5, the V H regions of the G3 and G9 immunoglobulins are not 
identical to that of T15. The G3 light chain also has at least one difference from 
Tl5 light chain. Our data suggest that among IgG immunoglobulins binding phos-
phorylcholine, sequence variation will occur within T15 idiotype-positive clones. 
Summary 
The hybridoma antibodies binding phosphorylcholine have provided important 
insights into the nature of diversity patterns in the V H' the D, and the JH segments. 
A striking feature of these antibodies is that the diversity in V H segments derived 
from IgG and IgA antibodies is significantly greater than that seen in the V H segments 
from IgM antibodies. Certain positions in IgG V H segments have a relatively high 
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probability of accumulating amino acid substitutions. Finally, these data provide 
formal proof of the first unequivocal example of the combinatorial association of 
light and heavy chains and are consistent with the hypothesis that combinatorial 
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Chapter 4 
The complete V domain amino acid sequences 
of two myeloma levan-binding proteins 
This manuscript will be submitted to the Journal of Immunology 
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The amino acid sequence analysis of groups of myeloma proteins binding various 
haptens has provided insights into the structure (1-5), function (6, 7), genetics (8-10), 
and evolution (11) of antibody molecules. The myeloma proteins binding levan are 
appropriate in several regards for the study of the properties of antibody V domains. 
First, the amino acid sequence analysis of the variable regions of light (V L) and 
heavy (V H) chains from myeloma proteins binding levan demonstrate that their diversity 
is limited in extent. The nearly complete V L sequences from three such myeloma 
proteins demonstrate that they differ from one another by four to seven residues 
(3). Likewise, the V H regions from four myeloma proteins binding levan differ from 
one another by one to three residues (4). This limited diversity facilitates structure-
function correlations, since critical amino acid interchanges are not obscured by 
other V region variability. Second, the affinities of the levan-binding myeloma pro-
teins for oligosaccharides of different lengths have been studied (12-14). As a result, 
amino acid substitutions can be correlated with antigen specificity. Lastly, Lieberman 
et al. (15) have extensively studied the cross-reacting idiotypes of levan-binding 
myeloma proteins. The structure of these proteins provides an important basis for 
a more detailed understanding of the molecular nature of V region idiotypes (3). 
In this report, we present the complete V domain sequences (V L and V H) of 
two additional immunoglobulins with specificity for levan. An analysis of these 
V domain sequences and sequences reported elsewhere reveals interesting patterns 
of V region diversity, and allows correlations to be drawn between V region structure, 
cross-reacting idiotypes, and antigen binding. 
MATERIALS AND METHODS 
Myeloma protein isolation. The BALB/c plasmacytomas W3082 (IgA, K) and 
J606 (IgG3, K) were obtained from the Salk Institute for Biological Sciences. Ascites 
was collected from these tumors and ammonium sulfate precipitations carried out 
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at 4°C for 2 hr in 40% saturated ammonium sulfate. Ammonium sulfate-precipitated 
protein was dissolved in 0.3 M NH5co3 and immunoprecipitated with inulin (Nutritional 
Biochemicals Corporation). Optimal amounts of inulin were determined separately 
for each precipitation. Two hundred ml of ascites typically required 100 mg of inulin. 
Chain separation. Myeloma protein-inulin precipitates were suspended in 0.5 M 
Tris-HCl, 2 mM EDTA, pH 8.2, and a 10% inulin solution was added dropwise until 
the precipitate dissolved. Dithiothreitol was added to a concentration of 50 mM 
and allowed to react for 2 hr at room temperature. The solution was then cooled 
to 0°C and iodoacetamide .added to 110 mM. After 2 hr, guanidine-HCl was added 
to a concentration of 3 M or 5 M. The light and heavy chains of the W3082 protein 
were routinely separated in 3 M guanidine-HCl, 0.2 M NH5 CO 3 on LKB Ultrogel 
AcA34. Because of the relative insolubility of the IgG3 heavy chain, the J606 immuno-
globulin chains were separated in 5 M guanidine-HCl, 0.2 M NH5co3 on Sephadex G-150. 
Cyanogen bromide digests. Cyanogen bromide digests were done in 70% formic 
acid, 2.5% cyanogen bromide at a protein concentration of 10 mg/ml for 24 hr at 
4°C. The digests were lyophilized twice and chromatographed on Ultrogel AcA34, 
AcA44, or AcA54 in 3 M guanidine-HCl, 0.2 M NH
5
co3• In some cases cyanogen 
bromide fragments were reduced and alkylated as above, except that guanidine-HCl 
was added to the reduction-alkylation buffer to 5 M. 
Desalting. All column pools were desalted in 0.2 M NH
4
0H on Sephadex G-10 
with the exceptions of W3082H CN2 and J606HCN4 (see Results for identification 
of CNBr fragments). These were desalted in 5% HC0
2 
on Biogel P-2 due to their 
insolubility in 0.2 M NH
4
0H. 
Enzyme digests. Trypsin, chymotrypsin, thermolysin, and a lytic protease 
digests were done at a 1:100 (w:w) enzyme:substrate concentration in 0.1 M NH5co3 
at 37°C with four hourly aliquots of enzyme. Carboxypeptidase A was used at 1:100 
enzyme:substrate ratio at room temperature in 0.2 M NH5co3 and aliquots were 
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removed from the reaction mixture at 2.5 min intervals for the first 10 min followed 
by ten 5 min and four 15 min intervals. Carboxypeptidase A was inactivated by 
boiling and all aliquots were analyzed on a Durrum D-500 amino acid analyzer. 
Norleucine was added to the enzyme digest as an internal standard. 
Chromatography and electrophoresis. Two-dimensional paper chromatography 
and electrophoresis was performed as described previously (16). Analytical maps 
were dipped in 0.1 % ninhydrin, 60:20:8 ethanol:acetic acid:collidine and heated at 
100°C for 12 min to develop the colors. Preparatory maps were sprayed with 0.1 % 
ninhydrin in ethanol, heated at 100°C to develop the colors, and the spots cut out 
and eluted as soon as they were visible. Acidic spots were eluted with 0.5 M ammonia 
and basic spots with 10% formic acid. 
Succinylation. Succinylation reactions were performed in 5 M guanidine, 0.2 M 
Tris buff er using a 20-fold weight excess of succinic anhydride. The succinic anhydride 
was added in six aliquots over 30 min, while the pH was regulated at 9.5 using 3 M 
NaOH and an automatic titrater. 
Tryptophan cleavage. Tryptophan cleavages were performed at room temperature 
in 35% cyanogen bromide, 1:1 88% formic acid:heptafluorobutyric acid as described 
in ref. 17. Tryptophan cleavage products were fractionated on Sep had ex G-50 in 
0.2 M NH5co3• 
Ion exchange chromatography. Peptides were fractionated on an ion exchange 
column of carboxymethylglycophase-controlled pore glass (Corning) using a concave 
gradient from 0.01 M sodium citrate, 8 M urea, pH 6.0 to 0.2 M sodium citrate, 1.5 M 
NaCl, 8 M urea, pH 6.0. 
Automated sequence analysis. Automated sequential degradation was performed 
on a Beckman 890B sequenator and on a modified 890B (18). Amino acid analysis, 
gas chromatography (19), and high performance liquid chromatography (18) were 
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used to analyze the PTH amino acid derivatives. Variable regions are numbered 
according to Kabat, Wu and Bilofsky (20). 
Isolation of heavy chain peptide 35-82. The CN2 fragment of W3082 was dissolved 
in 5% formic acid and 10% concentrated NH40H was added dropwise until a precipitate 
formed. After standing at 0°C for several hours, the precipitates were spun down 
and lyophilized. This technique is adapted from ref. 1. 
Subtractive Edman degradations. Subtractive Edman degradation was done 
as in ref. 21. 
RESULTS 
Isolation of heavy chain cyanogen bromide fragments. Purified W3082 and 
J606 heavy chains were digested with cyanogen bromide and fractionated by column 
chromatography as shown in Figure 1. The heavy chain from W3082 was run on Utrogel 
AcA44 and yielded two peaks, W3082H CNl and W3082H CN2 {Fig. lA). This frag-
mentation pattern is similar to that of Vrana et al. (4). The W3082H CNl fragment 
contained the V region sequence from positions 19 to 34 and from 82a into the C 
region. This fragment was desalted, lyophilized, fully reduced and aklylated, and 
then rechromatographed on AcA44 (Fig. lC) to yield the 82a to C region fragment 
as W3082H CNlc and the 19 to 34 peptide as W3082H CNld. The W3082H CN2 fragment 
(Fig. lA), containing the sequence from positions 35 to 82, was further purified by 
precipitation as described in Materials and Methods. 
The J606 heavy chain was digested with cyanogen bromide and run on AcA34 
(Fig. lB). The J606H CN4 fragment contained only the peptide from positions 35 
to 82 while the J606H CNl peak was a mixture of several peptides. The J606H CNl 
fragment was fully reduced and alkylated, run on AcA44, and the CNlb and CNle 
peaks collected {Fig. lD). Ion exchange chromatography on CNlb was used to isolate 
the peptide CNlbS , which extended from 82a into the C region (Fig. lE). The CNle 
fragment is the peptide extending from positions 19 to 34. 
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Figure 1. The cyanogen bromide fragmentation patterns of the heavy chains from 





• A. Mildly reduced and alkylated W3082H digested with cyanogen 
bromide and chromatographed on AcA44. B. Mildly reduced and alkylated J606H 
digested with cyanogen bromide and chromatographed on AcA34. C. Fully reduced 
and alkylated J606H CNl chromatographed on AcA44. D. Fully reduced and alkylated 
W3082H CNl chromatographed on AcA44. E. The J606H CNlb peak from C. run 
on carboxymethyl-glycophase-controlled pore glass. Peaks were eluted with increasing 
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Heavy chain sequence determination. Sequencing strategies for the V H regions 
from W3082 and J606 are summarized in Figure 2. The N-terminal 34 residues of 
the V H region from W3082 were determined from sequenator runs on the intact 
W3082 heavy chain and on the CNld fragment. The residues between 35 and 82 
were identified by a single sequencer run on W3082H CN2p with the exception of 
certain serines and the C-terminal two amino acids. These missing residues 
were determined by compositional data and sequence analyses of peptides produced 
by tryptic, alpha-lytic protease, and simultaneous tryptic plus chymotryptic digestions. 
A single sequenator run on the CNlc fragment identified the remaining V H region 
residues. 
The heavy chain from J606 was sequenced in much the same way as the W3082 
heavy chain. The N-terminal 34 residues were identified with N-terminal sequence 
analyses of the intact heavy chain and the CNlh fragment. Residues 35-82 were 
mostly identified with an N-terminal sequenator run on the CN4 fragment. Trypsin, 
chymotrypsin, alpha-lytic protease, and carboxypeptidase A were used to identify 
the C-terminal residues of the CN4 fragment. A single run on the CNlbS fragment 
was adequate to determine the remainder of the V H region sequence. 
Isolation of cyanogen bromide fragments from light chains. Purified light 
chains from W3082 and J606 yield identical patterns when cleaved with cyanogen 
bromide and chromatographed on Ultrogel AcA54 (Fig. 3A). The CN2 fragment corresponds 
to a peptide extending from positions 82-214 and the CN4 fragment is a partially 
separated mixture of peptides extending from positions 5-83 and 84-175. This chro-
matographic fractionation pattern is similar to that in ref. 3. The CN4 fragment 
was isolated, succinylated, cleaved at tryptophane with cyanogen bromide and 
fractionated on Sephadex G-50 (Fig. 3B). The second peak (CN3b) showed a single 
sequence starting at 35. Intact light chains also were digested with thermolysin 
to yield the peptide extending from positions 78-86. 
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Figure 2. Sequencing strategies for the heavy chain from J606 and W3082. 
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Figure 3. The cyanogen bromide fragmentation patterns of the light chains from 
J606 and W3082. Light chains from W3082 and J606 gave identical cyanogen bromide 
fragmentation patterns. A. A cyanogen bromide digest of fully reduced and alkylated 
W3082L chromatographed on AcA54 in 3M guanidine, 0.2 M NH5co3• B. The CN4 
peak from A. succinylated, cleaved at tryptophane residues, and chromatographed 
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Light chain sequence determination. The J606 and W3082 light chains were 
sequenced by the strategies shown in Figure 4 for W3082L. The N-terminal 38 residues 
were determined by sequenator runs on intact light chains. Sequenator runs on the 
CN4 peptides (residues 84-214, Fig. 3a) identified the residues from 84 into the 
C region. The residues from 35-81 were identified by sequenator runs on the CN4b 
peptides (residues 35-83, Fig. 3b), and residues 82 and 83 were determined by sequence 
analysis of the thermolysin overlap peptide from 78-86. 
DISCUSSION 
VII regions from myeloma immunoglobulins binding levan show variability 
primarily in framework positions. Figure 5 shows the complete sequences of six 
heavy chains from myeloma proteins with specificity for levan. These six heavy 
chain sequences differ from the A4 prototype sequence by one to three substitutions, 
only one of which occurs in a hypervariable region. Each of the nine amino acid 
interchanges requires only a one-base substitution and each occurs at a different 
V region position. This pattern of substitutions in the levan V H regions differs in 
a striking manner from those noted for the V H regions from immunoglobulins binding 
phosphorylcholine (1, 22-24), dextran (9), and galactan (25). In each of these latter 
examples, a substantial fraction of the variant residues lie within the hypervariable 
regions. Sixteen V H regions from myeloma and hybridoma immunoglobulins binding 
phosphorylcholine differ in 47 positions, 36 of which are in hypervariable regions. 
Twenty-one V H regions from myeloma and hybridoma proteins binding dextran differ 
by only 24 framework residues out of a total of 78 amino acid substitutions. Four 
galactan-binding myeloma V H regions differ by eight hypervariable residues and 
12 framework residues. Thus the V H regions from myeloma proteins binding levan 
have more conserved hypervariable regions than any other well-studied set of immuno-
globulin heavy chains with specific antigen-binding properties. 
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Figure 4. Sequencing strategies for the light chains from J606 and W3082. The 
sequencing strategies were the same for both J606L and W3082L. Symbols are as 
in Figure 2 with the exception of ( 
digest. 












































































































































































































































































































































































Figure 5. The complete sequences of six V H regions from myeloma proteins with 
specificity for levan. Unbroken lines indicate identity to the prototype sequence 
from the A4 protein. Substitutions are designated using the one-letter code of Dayhoff 
(29), and their positions are labeled at the bottom of the figure. Hypervariable regions 
(HVl, HV2, HV3) and the V, D, and J segments are as shown. The V H sequences 















































































































































































































































The conservation of heavy chain hypervariable regions from myeloma proteins 
binding levan may reflect fairly strict structural constraints imposed by antigen 
binding. The framework regions, while more diverse than the corresponding hyper-
variable regions, are not more diverse than framework regions of other V H regions 
with identified antigen-binding specificities. 
The VII segments from myeloma proteins binding levan are probably encoded 
by at least two closely related germline genes. Antibody V H regions are encoded 
by three distinct gene segments, V H' D, and JH. DNA analyses demonstrate that 
the V H gene segment from myeloma proteins binding levan extends from codons 
1-92; the D gene segment codes for positions 93, 94, and the first nucleotide of 
95; and the J gene segment extends from the second nucleotide of codon 95 to codon 
113 (26). Antibody V gene segments which differ by one or a few single base substitutions 
(such as those seen in Fig. 5) are frequently thought to arise as somatic variants 
from a single germline V gene segment (25, 27). 
This traditional view would suggest that the V H segments from myeloma proteins 
binding levan arise from a single germline V H gene segment encoding the prototype 
A4 and El 09 sequences. A V H gene segment that codes for the J606 V H segment 
has recently been isolated and sequenced (S. Crews, personal communication). Since 
this V H gene segment was isolated from a BALB/c sperm genomic library, the J606 
V H segment must represent a germline sequence. Traditionally, however, the A4 
V H segment would be considered to be the germline sequence for this group of proteins. 
This paradox can be resolved in one of three ways. i) The J606 germline gene gave 
rise to the other five V H segments by somatic mutation. This would require parallel 
substitutions in all of the V H segments but J606. ii) The V H regions from levan 
binding proteins may be encoded by two extremely closely-related V H segments, 
J606 and A4. iii) The J606 and A4 V H gene segments may represent polymorphic 
forms of a single genetic locus. 
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Levan-binding heavy chains have only one D segment substitution. As a result 
of D segment diversity, the third hypervariable region is the most variable part 
of an immunoglobulin heavy chain. This is clearly true of the V H regions from myeloma 
proteins binding phosphorylcholine (1, 22-24) and dextran (9), where, respectively, 
57% and 62% of the total V H diversity lie in the D segment. In the galactan-binding 
V H regions, the D segment is somewhat less diverse, accounting for 35% of the total 
diversity (25). 
In contrast to the D segments from proteins binding phosphorylcholine, dextran, 
and galactan, there is only one D segment substitution in the heavy chains from 
proteins binding levan. This lack of D segment variability corresponds to the lack 
of variability in other V H hypervariable regions, and may be due to selection by 
antigen. Alternatively, it may reflect an unknown restriction in the association 
of certain V H and D gene segments. 
The V L regions from myeloma proteins binding levan show diversity in the 
framework as well as in the hypervariable regions. The six V L regions from myeloma 
proteins binding levan are each different from one another, varying from the prototype 
sequence (061) by one to four residues (Fig. 6). These V L regions differ by 12 sub-
stitutions, 11 of which can be explained by one-base changes and one by a two-base 
change. Eight of these substitutions are in hypervariable regions. Unlike the V H 
regions, several substitutions in the V L regions occur at the same position. There 
are three V L regions with identical substitutions at position 30, two identical substitutions 
at position 92, and two proteins each with nonidentical substitutions at positions 
53 and 65. Thus nine out of 12 substitutions occur at four positions. 
Light chains from myeloma proteins binding levan have parallel substitutions 
which show no correlation with one another. Positions 30 and 92 each have substitutions 
that appear two times in five examples. The residue alternatives at positions 30 
and 92 assort ill such a way that all four possible combinations of residues at these 
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Figure 6. The sequences of five V L regions from myeloma proteins with specificity 
for levan. Sequences are diagrammed and labeled as in Figure 5. ( ) indicates 
a probable residue assignment and the gap in the A47 V L region is an area of unknown 







































































































































































































two positions occur. Thus both serine and asparagine at position 30 occur in chains 
having both threonine and serine at position 92. The variability at positions 30 and 
92 could arise in one of three ways as illustrated in Figure 7. i) The four V 
1 
segments 
may be directly encoded in the germline (Fig. 7 A). This possibility is unattractive 
because of the close similarity of the V gene segments. ii) These variants could 
K 
arise by the somatic mutation of germline genes. If there are one, two, or three 
germline V 
1 
segments, then this somatic mutation would require either mutation 
to a preexisting germline sequence or to a preexisting somatic sequence (parallel 
mutation). Figure 7B shows a somatic mutation pathway which could generate the 
observed sequences from one germline V 
1 
gene segment. In the case of the residues 
at V 
1 
position 30, somatic mutation must create identical substitutions in three 
different individuals. iii) Somatic recombination between two closely related V 
1 
gene segments could generate the four possibilities (Fig. 7C). The first possibility 
could be distinguished from the other two possibilities by sequence analysis of germline 
V H gene segments. Unless one postulates parallel somatic mutations (Fig. 7B), these 
theories require at least two very closely related germline V 1 gene segments encoding 
the V 1 segments of myeloma proteins with specificity for levan. 
Sequence correlates of antigen binding. The data presented here provide an 
example of how sequence data and antigen-binding studies can complement each 
other in making structure-function correlations. The hypervariable region sequence 
correlates of antigen binding are presented in Table 1 along with the length of oligo-
fructosan bound with maximum affinity by each myeloma proteins (12-14). The 
heavy chain hypervariable regions without sequence diversity are not shown. The 
only obvious correlation between the length of oligofructosan bound with maximum 
affinity and hypervariable-region sequence occurs in the second hypervariable region 
of the light chain. Here the presence of a residue other than isoleucine at position 53 
is associated with maximum affinity for a tetrasaccharide, while isoleucine at position 
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Figure 7. Mechanisms for the generation of diversity at residues 30 and 92 in the 
V L regions of myeloma proteins with specificity for levan. The amino acid residues 
at positions 30 and 92 encoded by the V L gene segments are labeled using the one-
letter code of Dayhoff. N = asparagine, S = serine, T = threonine (29). 
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A. Four germline V L gene segments 
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Hypervariable region comparisons among levan-binding myeloma proteins. The V L 
(HVl, HV2, HV3) and VH (HV2) hypervariable region differences are depicted for 
each myeloma protein. Substitution positions are shown above the amino acid 
interchanges. The oligosaccharide-binding affinity of W3082 is from ref. 12, the 
affinity of J606 is from ref. 13, and the affinities of A47, A4, U61, and E109 are 
from ref. 14. Binding affinities are discussed in ref. 5. 
v
1 
region VH region 
HVl HV2 HV3 HV2 
-30- -53-56- -92- -53-
Proteins with J606 -Ser- -Asn-Asp- -Ser- -Asn-
maximum affinity A47 -Ser- -Thr-Asp- -Thr- -His-
for tetrasaccharide A4 -Asn- ? ? -His-
Proteins with U61 -Ser- -Ile-Asp- -Ser- -His-
maximum affinity E109 -Asn- -Ile-Ala- -Ser- -His-
for pentasaccharide W3082 -Asn- -Ile-Asp- -Thr- -His-
118 
53 is associated with maximum affinity for pentasaccharide . The aspargine-serine 
interchange at V L position 30 and the threonine-serine interchange at V L position 92 
do not cause a reduction in the length of oligosaccharide required for maximum 
affinity. However, it is possible that the asparagine-histidine interchange at V H 
position 53 limits the size of the J606 levan-binding site. Thus, antigen-binding 
data can be used to determine the possible effects of amino acid substitutions. 
Amino acid substitutions which correlate with antigen binding are possible sites 
of selection by antigen. Such selection might operate if an antigen stimulated only 
those clones with certain antigen-binding specificities to divide. 
The structures of the V domains from myeloma proteins binding levan provide 
fundamental insights into the nature of idiotypic determinants. The V domains of 
the levan-binding myeloma proteins afford a unique opportunity to make correlations 
between idiotype specificities and primary amino acid sequence because i) the complete 
V H sequences are known for six myeloma proteins and the complete V L sequences 
are known for four and part of a fifth protein; ii) th~ idiotypic specificities of these 
proteins have been extensively analyzed (Table 2) (15); and iii) these proteins generally 
differ in their V domains by only a few residues from one another (Figs. 5 and 6; 
Table 2). Accordingly, it is possible to determine some of the molecular properties 
of the crossreacting idiotypes shown in Table 2. 
Lieberman et al. have reported a comprehensive study of the idiotypes of 
myeloma proteins which bind levan, including the six proteins shown in Figures 5 
and 6 (15). Using antisera raised against these levan-binding myeloma proteins, 
they have defined 10 crossreacting idiotypes (IdX) and determined the hapten inhibitability 
of each IdX specificity. Their IdX specificity assignments are shown in Table 2. 
IdX specificities are determined by the ability of myeloma proteins to inhibit the 
hemagglutination of red blood cells coated with levan-binding myeloma proteins. 


















































































































































































































































































































































































































































































































































































































with antisera raised against W3082. Levan-binding myeloma proteins which inhibit 
this hemagglutination are typed as carrying the ldXA determinant. The numbers 
in Table 2 ref er to the -log2 of the dilution of a 1 mg/ml solution of myeloma protein 
necessary for the inhibition of hemagglutination of an IdX typing assay. Table 2 
also contains a schematic representation of the amino acid interchanges in the levan-
binding myeloma proteins. In the following section, we discuss correlations between 
IdX determinants and V domain amino acid interchanges. 
The IdXA and ldXC idiotypes. The ldXA and ldXC specificities have identical 
distributions and are hapten-inhibitable (Table 2). They are present on the myeloma 
proteins U61, A4, W3082, and E109. The only residue shared exclusively by these 
molecules is the isoleucine at position 53 in the V 
1 
region (the residue in A4 is unknown). 
It is tempting to postulate a structural correlation between V L residue 53 and ldXA; 
however, it has been shown that ldXA is dependent only on the heavy chain (28). 
Since the A47 protein (IdXA -, ldXC-) and the W3082, E109, U61, and A4 proteins 
(IdXA +, ldXC+) have identical V H hypervariable regions, the hapten-inhibitable IdXA 
and IdXC determinants must include framework as well as hypervariable region 
residues. 
The ldXB and ldXF idiotypes. The ldXB and IdXF specificities have identical 
distributions (Table 2). The ldXB specificity is situated primarily on the light chain 
(28) and is hapten-inhibitable. These idiotypes correlate best with residues 53 and 
56 in the C-terminal part of the second V L hypervariable region. Our data contradict 
the conclusions of Vrana et al. who suggested that the ldXB idiotype correlated 
with serine residues at V L positions 30 and 92 ( 3 ). The W3082 protein has the IdXB 
idiotype and has asparagine at position 30 and threonine at position 92. 
The ldXE and ldXG idiotypes. The ldXE and ldXG specificities are difficult 
to assign in that they are present on all of the myeloma proteins but the A4 7 protein, 
which is not completely sequenced. 
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The IdXH idiotype. The IDxH idiotype is hapten-inhibitable and present only 
on the A4 and U61 proteins. The U61 and A4 proteins share their V H hypervariable 
regions with all of the levan-binding myeloma proteins except for the second hyper-
variable region of the J606 protein. Each of the V 
1 
hypervariable regions of the 
061 and A4 proteins are shared with at least three other V 
1 
regions (only the first 
V 
1 
hypervariable region from A4 has been sequenced). The 061 protein does not, 
however, share all of its V 
1 
hypervariable regions with any one V 
1 
region and thus 
the IdXH specificity could be dependent on all three hypervariable regions. Alternatively, 
the IdXH idiotype could be determined by framework as well as hypervariable regions. 
The IdXI idiotype. The ldXI specificity is present on all the myelomas. It 
is impossible to correlate it with particular V region residues. 
The IdXJ idiotype. The IdXJ specificity is not hapten-inhibitable even though 
it is correlated with the threonine residue at position 92 in the V 
1 
third hypervariable 
region. Hence, either the threonine at position 92 does not participate in antigen 
binding, or the IdXJ specificity is dependent on residues in other parts of the V domain. 
This discussion correlating idiotypic specificities with V domain structure 
for the myeloma proteins binding levan is admittedly incomplete. It does, however, 
emphasize some general ideas about idiotypy which are important in using idiotypes 
as an assay for antibody V region structure. These ideas are the following: i) Distinct 
idiotypes can arise from the same amino acid interchange. The J606 and 061 proteins 
differ by four hapten-inhibitable idiotypes and at the same time differ by only three 
amino acid substitutions of which only two are in hypervariable regions. Thus, single 
amino acid residues can be involved in determining multiple idiotypic sites. One 
possible mechanism for this is that certain amino acid interchanges may cause major 
conformational alterations in the V domain, thus generating new idiotypic sites. 
Alternatively, idiotypic sites may overlap so that several idiotypes encompass the 
same amino acid residue. ii) Hapten-inhibitable idiotypes may depend on residues 
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both within and outside the hypervariable regions. For example, the IdXA idiotype 
is present on the heavy chains of the W3082, U61, A4, and E109 proteins. These 
heavy chains have identical V H hypervariable regions to the A4 7 protein, which 
lacks the IdXA specificity. Thus, the hapten-inhibitable IdXA idiotype must be dependent 
on residues outside as well as residues inside the antigen-binding site. iii) Anti-idiotypic 
antisera may concentrate on certain portions of the antibody V domain. It is possible 
to make correlations between idiotype and structure for seven of the ten IdX determinants 
(all but ldXE, IdXG, and ldXI). Three of the seven idiotypes correlate with the C-
terminal portion of the V 
1 
second hypervariable region. Hence, several IdX determinants 
may be concentrated in a particular region of the V domain and fail to identify variation 
in other areas. For example, the J606 and E109 proteins share more idiotypes than 
the J606 and U61 proteins. The J606 and U61 proteins differ by four idiotypes while 
the J606 and E109 proteins differ by only three. The J606 protein, however, differs 
by only three amino acid substitutions from the U61 protein and by nine substitutions 




The myeloma proteins binding levan afford a unique opportunity to study the 
V region patterns of variation because of the similarity in their V 1 as well as their 
V H regions. The diversity patterns in both the V 1 and V H regions suggest that these 
proteins are encoded by multiple, very similar V gene segments or that somatic mutation 
to preexisting sequences can occur. Because of the close similarity in the V domains 
of these proteins and the extensive idiotypic analyses that have been previously 
carried out, several interesting conclusions can be drawn about the nature of idiotypic 
determinants. First, distinct idiotypes can arise from the same amino acid inter-
change. Second, hapten-inhibitable idiotypes may depend on residues within and 
outside the hypervariable regions. Third, idiotypic similarity does not always predict 
a corresponding sequence similarity. In addition, antigen binding studies allow the 
roles of amino acid interchanges in antibody-antigen interactions to be investigated. 
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This dissertation is primarily a discussion of antibody diversity as seen in sets 
of immunoglobulin V regions with similar amino acid sequences. As a summary, 
I would like to describe my personal view of antibody diversity. This description 
will combine experimental observations with a large dose of speculation, and will 
be concluded with several ideas about future directions of research. 
The diversity of IgM antibodies is less than that of IgG and IgA antibodies 
(1-3). Because of this, and because IgM antibodies precede IgG and IgA antibodies 
in ontogeny (4), I will discuss IgM diversity first. The experiments reported in this 
dissertation were designed to allow the analysis of patterns of antibody V region 
diversity. The kinds of V region diversity which are observed are necessarily restricted 
by the relatively small numbers of closely related V regions available for analysis 
(partial sequences from 29 phosphorylcholine-binding antibodies are included in 
Chapter 2). 
An initial consideration in a discussion of antibody diversity is, what is the 
nature of the diversity in newly formed B cells in the bone marrow? I feel that 
this diversity has the following properties: (i) first, heavy chain-light chain com-
binatorial association leads to nearly complete mixing of V 
1 
and V H regions. (ii) In 
addition, gene segment joining mechanisms will lead to the assortment of all V 1 
gene segments with all J1 gene segments and all V H gene segments with all D and 
JH gene segments (5-8). Thus the immature cells arising from the bone marrow 
will express all possible V 1 and J1 gene segment combinations with all possible V H' 
D, and JH gene segment combinations. (iii) Finally, somatic mutation other than 
the junctional diversity discussed below does not generate significant V gene vari-
ability in new B cells. 
It has been estimated that the number of germline V 1 gene segments may 
be around 200 (9), and V H gene segments may number about the same. There seem 
to be four functional J
1 
gene segments (10, 11) and four JH gene segments (7, 12), 
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and I will guess that the number of D gene segments is five. V L -JL junctions seem 
to give rise to six junctional sequences as a result of DNA joining mechanisms (8), 
but no estimate of comparable quality is possible for V H-D-JH junctions. In the 
phosphorylcholine-binding antibody system there are five V H-D junctional sequences 
and perhaps five D-J H junctional sequences which seem to arise as strictly "junctional" 
diversity (not as a result of D segment combinatorial joining) (1-3). Using the above 
speculations about gene segment combinatorial joining and numbers of gene segments, 
one can estimate the total germline antibody V L region repertoire to be: 200 (V L) x 6 
(V L-JL junction) x 4 (JL) = 4.8 x 103 V L regions. Likewise, there would be 
200 (V H) x 5 (V H-D junction) x 5 (D) x 5 (D-JH junction) x 4 (J H) = 105 V H regions. 
Heavy-light chain combinatorial joining would then create 4.8 x 103 (V L) x 105 
(V H) = 4.8 x 108 antibodies. 
The B cells that leave the bone marrow circulate through the body and, after 
elimination or paralysis (13, 14) of self-reactive clones, mature into IgM-secreting 
cells (4). These IgM-secreting cells can then further differentiate to express different 
antibody constant regions (4, 15). What is the nature of the diversity in this pool 
of IgM producers? There are four important considerations. 1) A substantial 
amount of diversity is presumably eliminated because of self-reactivity, though 
it is impossible to guess how much. 2) During ontogeny, some clones will leave the 
bone marrow earlier than others. These clones will have a chance to undergo early 
clonal expansion and, in the absence of balancing influences, may retain a numerical 
advantage over later clones. 3) Antigen can selectively expand antigen-reactive 
clones. Cells leaving the bone marrow early will acquire an additional numerical 
advantage if they encounter antigen before other clones with similar specificity 
appear. 4) Antibody production has been postulated to be controlled by idiotype-
antiidiotype networks (16-18). Antiidiotypic antibodies or T cells may routinely 
enhance or depress antibody responses. Thus I envision the IgM-producing B cell 
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pool as a collection of clones present at widely differing clonal frequencies. Clones 
which left the bone marrow early and were quickly triggered by antigen will be present 
at high frequencies, while unstimulated clones which arose relatively late will be 
present at very low frequencies (perhaps one or a few cells per mouse). If antibody 
V 1 and V H regions are expressed in a program med order, cells producing specific 
heavy-light chain combinations may be present at similar frequencies in different 
individuals (19, 20). 
IgA- and IgG-producing cells show greater V region diversity than IgM-producing 
cells (1). There are two major considerations in the generation of this increased 
IgG and IgA diversity. First, when and how is the additional variability in IgG and 
IgA antibodies created? And second, what is the mechanism by which this additional 
diversity reaches a relatively high frequency in IgG and IgA antibodies? These 
questions are discussed in Chapter 2, and so I will use this section to just emphasize 
those points which I feel are important. I feel that a great deal of the additional 
IgG V segment variability in the antiphosphorylcholine response is due to somatic 
mutation. Most importantly, I feel that the V segment variability arising repeatedly 
at V H positions 40 and 53 in phosphorylcholine binding proteins (3) is due to somatic 
mutation. Thus somatic mutation seems to give rise to certain V H segment variants 
in a reproducible manner. Additionally, I feel that somatic mutations are created 
initially in a single cell. Their detection in my study of phosphorylcholine-binding 
V H regions suggests that such somatic mutants have been expanded, either clonally 
or as a population, to a level wfiere they play a significant role in immunity. This 
expansion has presumably occurred in the face of a strong, germline response to 
phosphorylcholine. Therefore it is conceivable that even somatic mutants at low 
frequencies could expand in response to antigen at a fast enough rate to increase 
the effective available antibody diversity. 
The kinds of selection which may operate to generate IgG and IgA diversity 
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are also discussed in Chapter 2 (1). I will add that I feel that both antigen binding 
and antiidiotypic network regulation of antibody are important selective forces. 
Selection by antigen is probably on the basis of antibody affinity, though this assump-
tion is difficult to test' experimentally. Antibody affinity measurements performed 
with free antibody and hapten in vitro may bear little relationship to the affinity 
of cell surface antibodies for hapten-protein antigens in vivo. Artificially induced 
selection by antiidiotypic antibodies is well documented in experimental animals 
(17, 18, 21). A particularly simple selection model postulates that antiidioype inhibits 
the growth of high frequency clones. Thus infrequent clones would always be at 
an advantage, tending to maintain antibody heterogeneity. A high level of antibody 
heterogeneity would in turn give an organism versatility in responding to new antigens. 
IgG and IgA V regions would be more diverse than IgM V regions either because they 
have undergone more generations of selection, or because idiotypic regulation is 
specific for IgG and IgA producing cells. 
This, then, is an overview of my thoughts on antibody diversity. In the following 
section I will deal specifically with each major category of antibody diversity genera-
tion mechanisms. 
The germline V segment contribution to diversity. 
I feel that the germ line contribution to antibody diversity perhaps plays the 
most critical role of all antibody diversity generation mechanisms. Using the numbers 
mentioned previously, loss of all but one V Lor V H gene segment would reduce the 
antibody diversity by a factor of 200. V segments can be divided into groups differing 
by no more than three residues over their N-terminal 30 amino acids (22 ). These 
groups may differ by over 50% among each other. If there are approximately 30 
V L groups and 30 V H groups (9), then there are only 900 V group sets of germline 
antibody molecules. The differences, among these 900 V group sets will be much 
greater than those within a set, and the inter-V group set differences will extend 
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throughout the V segment. Thus germline V segment diversity and the diversity 
arising from somatic gene segment joining are not equivalent. An increase in D 
segment diversity probably would not compensate for a loss of V segment diversity. 
YL and V H third hypervariable region diversity. 
V H-D-JH and V L -JL junctional diversity and combinatorial joining creates 
a considerable amount of heavy and light chain third hypervariable region variability 
(2, 3, 5-8, 11). In fact, there is probably well over ten times the number of V L plus 
V H third hypervariable regions than all other hypervariable regions combined. Without 
VL-JL and VH-D-JH diversity, the total antibody diversity would be reduced by 
a factor of 4 (JL) x 6 (VL-JL) x 5 (VH-D) x 5 (D) x 5 (D-JH) x 4 (JH) = 1.2 x 104• 
Combinatorial association. 
Combinatorial association of heavy and light chains is a particularly powerful 
mechanism for diversity generation. 105 V H regions and 4.8 x 103 V L regions (see 
above) can generate at most 105 antibodies without combinatorial association, a 
reduction by a factor of 4.8 x 103 of the number of antibodies otherwise possible. 
Somatic mutation. 
The most difficult factor to assess is somatic mutation. In Chapter 3, it is 
suggested that certain patterns of variation arise repeatedly in the IgG and IgA 
pool (3). If these patterns of variation arise as a result of somatic mutation, then 
somatic mutation may well be quite reproducible. In addition, it has been suggested 
earlier in this summary that low level somatic variants may be effective at expanding 
the usable antibody diversity. Thus, organisms may be able to rely on generating 
a certain .amount of functional antibody diversity by somatic mutation, eliminating 
the need to retain such diversity in the germline. Special mutational processes might 
well evolve to enhance the creation of such somatic diversity (23, 24). 
In the above discussion I have emphasized the factors by which each mechanism 
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of diversity generation increases the antibody repertoire. In the cases of germline 
segment diversity, gene segment combinatorial joining and junctional diversity, 
and heavy-light chain combinatorial association, I feel that the factor by which 
each mechanism increases diversity is too large to be an evolutionary artifact. 
These mechanisms must make important contributions to immunity. 
Somatic mutation, on the other hand, may increase immunity by a much smaller 
factor. Somatic mutations may only be present in clones which are repeatedly stimu-
lated by antigen and hence undergo many rounds of division and clonal expansion 
and reduction. Thus somatic mutation is possibly the least important of all mechanisms 
of antibody diversity generation, even though it may be quite visible in the antibodies 
binding certain antigens. 
In the next section I will briefly discuss experimental approaches which address 
some of the points raised in this summary. 
Studies at the DNA level will eventually allow reasonable estimates of the 
number of germline V segments to be made. These estimates will permit a fairly 
accurate assessment of the germline V gene segment contribution to antibody diversity. 
Isolation and sequencing of germline D gene segments will probably also occur in 
the near future. It is important, however, to determine the extent to which D region 
combinatorial joining and D region junctional diversity actually occur during dif-
ferentiation. This question could be investigated in a fairly straig_htforward way 
at the subgroup level using cDNA library of splenic H chain mRNA. This library 
could be screened with an appropriate probe and the resultant clones analyzed by 
restriction digests and DNA sequencing. By screening with a V H segment probe 
only (no D segment) a broad collection of VH-D-JH cDNA combinations should be 
obtained allowing one to determine the extent of the D diversity associated with 
V gene segments from a particular group. 
In addition, such a splenic heavy chain cDNA library could be used for an 
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extensive study of D segment variability. DNA complementary to C region sequences 
at the V H-CH junction could be used as a primer for DNA sequencing studies of 
D segments from cloned cDN As. 
Combinatorial association of light and heavy chains is an old idea which has 
never been satisfactorily investigated. A.I light chains are encoded by only one or 
a few VA.I genes (25, 26) and presumably undergo combinatorial association to the 
same degree as K light chains. Thus determination of the V H sequences associating 
with A.I chains would provide a measure of heavy-light chain combinatorial association. 
Partial V H cDNA sequences from A.I-producing hybridomas could be determined 
using the dideoxy nucleotide DNA sequencing technique and primers complementary 
to immunoglobulin C regions (7). This experiment would provide information on 
D segment variability as well as on combinatorial association. 
A final question, and one which will be very difficult to answer, concerns the 
importance of each component of antibody diversity generation to immunity. The 
ideal experimental model would be a mouse lacking particular diversity mechanisms, 
e.g., mice with only a few V 1 or V H segments, one J1 or JH segment, or one D segment. 
Unfortunately, no such mice have ever been found. The new awareness of the roles 
of D and J segments, however, may eventually lead to the discovery of their involve-
ment in immunodeficiencies. Until then, the value of different mechanisms for 
generating antibody variability will continue to be judged on the basis of calculations 
such as those presented earlier. It is hard to imagine a way (short of stumbling 
across fortuitous mutants) of ever answering the fundamental question, "What are 
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The phenylthiohydantoins (Pth) of the common amino acids can be resolved in a single 
analysis using a 25 x 0.46-cm DuPont Zorbax cyanopropylsilane (CN) column developed 
with a gradient of methanol/acetonitrile (17:3) in s~~ium acetate.~u~er, pH 5.4. The Zorb~x 
CN columns exhibit greater durability, reproducib1hty, and sens1t1V1ty than do columns with 
an octadecylsilane (C18) support when used for Pth amino acid analysis in automated poly-
peptide sequencing. 
In the last few years, reverse-phase high-
pe1formance liquid chromatography (hplc )2 
has revolutionized protein sequencing ana-
lytical procedures (1-4). It provides rapid, 
sensitive, quantitative analysis of the Pth 
amino acids formed from the amino acids 
released during automated Edman degrada-
tion. Unlike the other techniques-thin-
layer chromatography (5), gas chromatog-
raphy (6), and back-hydrolysis to the pare~t 
amino acids (7 ,8)-commonly used for this 
analysis, hplc can resolve all the commonly 
encountered Pth derivatives in a single 
chromatographic run. In this report, we de-
scribe an hplc system for the Pth amino acid 
analysis using DuPont Zorbax CN columns 
rather than the more commonly used C1s 
columns. It provides greater column lifetime, 
higher sensitivity, increased column-to-
column reproducibility, and more reliab!e 
resolution of Pth-Arg and Pth-His than 
previously reported hplc analyses of these 
derivatives. 
1 Supported by NIH Grant GM 06965. 
2 Abbreviations used: hplc, high-performance liquid 
chromatography; Pth, phenylthiohydantoin; CN, 
cyanopropylsilane; ODS and C1s. octadecylsilane. 
MATERIALS AND METHODS 
Reagents. Acetonitrile and methanol were 
Burdick and Jackson distilled-in-glass sol-
vents. Sodium hydroxide and acetic· acid 
were Baker analyzed reagents. Water was 
first deionized and then distilled. Pth amino 
acid standards were obtained from Pierce 
Chemical Company. 
Chromatography equipment. The hplc unit 
consists of two Waters Associates Model 
6000A solvent delivery systems, a Waters 
model 710 autosampler, a Waters Model 440 
dual-channel (254 and 313 nm) absorbance 
detector, a Houston Instruments Omniscribe 
dual-channel chart recorder, a Caltech-con-
structed multilinear programmable gradient 
maker that controls the two Waters pumps, 
and a simple constant temperature oven. The 
oven houses a DuPont Permaphase ETH 
guard column (5 x 0.46 cm) and a DuPont 
Zorbax CN analytical column (25 x 0.46 cm) 
at 31 ± 1°C. The factory-installed sample 
loading loop of the Waters autosampler has 
been replaced with a 25-µ.l loop constructed 
of 0.0625-in.-o.d. x 0.009-in.-i.d. 316 stain-
less-steel tubing, and the line between the 
pump and the autosampler has been replaced 
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with 0.0625-in.-o.d. x 0.020-in.-i.d. 316 stain-
less-steel tubing. 
Pth amino acid analysis. The columns are 
equilibrated initially with pH 5.4 sodium 
acetate buffer (0.015-0.040 M) at a flow rate 
of 1.0 ml/min. The samples are dissolved in 
acetonitrile, loaded into the low-volume 
sample inserts for the autosampler, and in-
jected into the flow to the column. The Pth 
amino acids are eluted with an increasing 
concentration of a methanol/acetonitrile 
(17:3) mixture with the total buffer plus 
solvent flow rate held constant at 1.0 ml/min. 
The acetate buff er is made up fresh daily 
by diluting a 0.10 M stock solution and 
degassing it by boiling for 5 min. 
RESULTS AND DISCUSSION 
Pth Amino Acid Fractionation 
Figure 1 shows a typical elution profile of 
a mixture of 19 Pth amino acids from a 
Zorbax CN column. All 19 of the derivatives 
can be resolved (>9<m) with a 35-min column 
recycle time. In addition, several other Pth 
amino acids can be resolved with the same 
gradient. These include the Pth derivatives 
of carboxymethylcysteine (elutes 20 s before 
Pth-Glu), succinyllysine (elutes 60 s before 
Pth-Asn), and carboxamidomethylcysteine 
(elutes 30 s after Pth-Glu). 
Although Pth-Asn, -Ser, and -Thr elute 
within a 45-s period, they are >90% resolved 
because the peaks are very sharp. We have 
never experienced difficulty from their simi-
lar elution times in assigning a sequencer 
residue to these amino acids because (a) 
serine and threonine residues give multiple 
peaks in addition to Pth-Ser and -Thr and 
asparagine residues give some Pth-Asp in 
addition to Pth-Asn, and (b) there is always 
a background of most Pth amino acids in a 
sequencer sample that allows assignment of 
any large peak (such as Pth-Thr) relative 
to the background of smaller ones (the nearby 
Pth-Asn, -Ser, -Gln, and -Gly). Although the 
absolute retention times do vary by as much 
as 20 s from one run to another, the spacing 
between nearby peaks is nearly constant. 
Moreover, one can always cochromatograph 
a small amount of the authentic Pth derivative 
with the sample to confirm identification 
should there be no observable background. 
This resolution is in several respects 
superior to that attainable with DuPont 
Zorbax ODS columns, the only other col-
umns with which single-step resolution of 
all common Pth amino acids has been re-
ported (1,4). 
(i) The resolution of Pth-His and Pth-Arg 
from the other Pth amino acids is more easily 
maintained with the CN than with the ODS 
column. With the latter, Pth-His and Pth-
Arg often elute as broad peaks that overlap 
with those of other Pth amino acids. The 
peak broadening increases rapidly with col-
umn use, and although the effects of column 
aging can be compensated for somewhat by 
increasing the starting buffer concentration, 
these derivatives frequently are resolved 
only by using a much steeper eluting gradi-
ent. With the CN columns, they elute as 
sharp peaks throughout the usable lifetime 
of the columns. Although they tend to elute 
later at a given buffer concentration as the 
columns age, this effect can be compensated 
for by increasing the buff er concentration 
from -0.015 M for a new column to -0.040 
M for a column that has been used steadily for 
2-3 months. 
(ii) The usable lifetime (3 months with 
2500-3000 injections) of the CN columns 
is considerably longer than that of the ODS 
columns (3-6 weeks with 750-1500 injec-
tions) if resolution similar to that shown in 
Fig. 1 is required. Although we have not 
examined the cause of this difference sys-
tematically, we feel it is most likely due to 
the high column temperature (55-60°C) re-
quired for comparable resolution of all the 
Pth amino acids on the ODS columns. 
(iii) The sensitivity of the Zorbax CN 
columns as an analytical tool for quantitative 
analysis of Pth amino acid mixtures in auto-
mated protein sequencing experiments is 
· superior to that of C18 columns that have 
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FIG. 1. High-performance liquid chromatographic separation of Pth amino acids on DuPont Zorbax 
CN. The initial solvent (A) was 0.024 M sodium acetate buffer, pH 5.4, and the secondary solvent (B) was 
methanol/acetonitrile (17:3). The sample consisted of 10 µ.I ofacetonitrile containing 1 nmol of each of 
the Pth amino acids. Flow rate was 1.0 ml/min, and column temperature was 31°C. 
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been reported (1-4). The maximum peak 
absorbance per nanomole ranges from 0.06-
0.15 A~~ for the Zorbax CN columns com-
pared to 0.03-0.09 A~~m for C18 columns. 
This is due to the higher theoretical plate 
count of the CN columns and the gradient 
required for the Pth analysis. 
(iv) The Zorbax CN columns give repro-
ducible elution patterns for the Pth amino 
acids from one column to another. We have 
not had to change the gradient, solvent, 
buffer composition (other than concentration 
for Pth-His and Pth-Arg resolution), flow 
rate, or column temperature to achieve the 
resolution shown in Fig. 1 for the CN col-
umns we have used over a period of 18 
months. Nonreproducibility of the column-
to-column performance of Zorbax ODS for 
Pth-His and Pth-Arg often forced us to de-
vise separate gradients solely for their 
determination (4). 
The chief disadvantage of using the Zor-
bax CN rather than the C18 columns is the 
higher baseline absorbance rise during the 
gradient development due to impurities in 
most batches of hplc-grade methanol. In-
vestigators who need to use the higher sensi-
tivity photometer scales should either ask 
their supplier for lots with an ultraviolet 
wavelength cutoff of 204 nm (or less) or 
should repurify the methanol before use. 
Treatment of hp le-grade methanol by boiling 
for 10 min with activated charcoal, filtration, 
and distillation through a 40-cm Widmer col-
umn under argon has proven effective in our 
laboratory. With the 254-nm photometer in 
our hplc system, the gradient baseline rise 
can be as low as 0.002 with the redistilled 
methanol compared to 0.005-0.020 for vari-
ous batches of Burdick and Jackson meth-
anol. The acetonitrile-buffer system used 
for Zorbax ODS columns (1,4) or the metha-
nol-buffer systems used for Waters µBonda-
pak C18 columns (2,3) typically show an 
absorbance rise of0.005. Addition of acetone 
to the initial buffer to raise its 254-nm ad-
sorbance to the level of the eluting solvent 
(and hence minimize baseline rise during the 
gradient), although successful with the µ-
Bondapak C18 columns (2,3), is impractical 
with the Zorbax CN columns because of re-
tention of acetone on the column during 
the initial equilibration with buffer and 
subsequent elution of the adsorbed acetone 
during the gradient. 
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